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Breast cancer is the most common noncutaneous form of cancer among women in the US.  In 
recent years, the overall mortality rate has declined, yet there still exists a significant racial 
disparity in the incidence and mortality between African American and Caucasian women.  
While numerous hypotheses have been proposed to explain this difference, few offer a biological 
explanation. 
There is a well established association between estrogens and breast cancer risk, and the 
ratio of two estrogen metabolites, 2-hydroxyestrone (2OHE1) and 16α-hydroxyestrone 
(16OHE1), has been implicated as a marker of breast cancer risk.  
Many studies have also assessed the relationship between endogenous estrogens and 
mammographic density.  Mammographic density is one of the strongest predictors of breast 
cancer risk, but the mechanism by which it influences this risk remains unknown.  Nonetheless, 
few have examined mammographic density in relation to the 2OHE1:16OHE1 estrogen 
metabolite ratio (EMR). 
Research suggests that the Cytochrome P450 1B1 (CYP1B1) gene may also mediate 
breast cancer risk, as this gene is very active in estrogen metabolism.  In fact, the Leu432Val 
polymorphism has reportedly been associated with urinary levels of the 2OHE1:16OHE1 EMR. 
The objective of this study was to investigate some of the relationships found among the 
2OHE1: 16OHE1 EMR, CYP1B1 Leu432Val polymorphism, mammographic density, race, and 
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breast cancer risk.  The 2OHE1:16OHE1 EMR was associated with both breast cancer risk and 
the CYP1B1 Leu432Val polymorphism, yet, no association with breast cancer risk and this 
polymorphism was observed.  This suggests that if the CYP1B1 Leu432Val polymorphism alters 
breast cancer risk, it does so through variations in the 2OHE1:16OHE1 EMR.  When taking race 
into account, no association between mammographic density and the 2OHE1:16OHE1 EMR was 
observed.  In culture, evidence was found to suggest that the 2OHE1:16OHE1 EMR is 
influenced by subcellular effects or other intrinsic factors (i.e. genetic variation), as passage 
number was the only significant contributor to the 2OHE1:16OHE1 EMR. 
The results of this study have great public health significance, as it provides a better 
understanding of the risk factors, including racial differences, and etiology of breast cancer, 
which will ultimately lead to better prevention and treatment for all women. 
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1.0  INTRODUCTION 
Breast cancer is a complex disease influenced by both genetic and environmental factors.  It is 
the second most diagnosed cancer among women in the United States, and is the second leading 
cause of cancer-related deaths (American Cancer Society, 2009; National Cancer Institute, 
2008b).  While breast cancer affects women of all racial/ethnic groups, women of African 
descent suffer disproportionately higher mortality rates (American Cancer Society, 2008a).  
Given the unknown etiology of this disease, the focus of numerous investigations is on 
estimating and reducing the risk of developing breast cancer in all populations.  Scientists have 
now identified several risk factors that influence the likelihood of developing breast cancer.  
These include: increasing age, age at first full-term birth, early menarche, late menopause, 
mammographic density, family history, obesity, HRT use, Oral Contraceptive (OC) use, alcohol 
consumption, and physical inactivity (American Cancer Society, 2007; Key, Verkasalo, & 
Banks, 2001).  To date, there are only two known genes, with variable penetrance, that confer an 
autosomal dominant transmission of Hereditary Breast Cancer, BRCA1 and BRCA2.  However, 
the large majority of breast cancer is sporadic in nature, and occurs as a result of numerous 
somatic mutations in low–penetrant genes.  Nonetheless, epidemiological studies have 
established an association between estrogens and breast cancer risk, as the large majority of these 
risk factors are hormonally driven. 
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There are three naturally occurring types of estrogen: estradiol, estrone, and estriol, all of 
which are under the control of the Cytochrome P450 superfamily of genes (Johnson, 2008; 
Marieb, 2009).  The parent molecule, 17–β estradiol, is oxidized into three distinct 
catecholestogens, 2–hydroxyestrone (2OHE1), 4–hydroxyestrone (4OHE1), and 16α-
hydroxyestrone (16OHE1), all of which are catalyzed by the CYP1B1 gene (Badawi, Cavalieri, & 
Rogan, 2001; Cribb et al., 2006; Lord, Bongiovanni, & Bralley, 2002; Mueck, Seeger, & Lippert, 
2002; Tsuchiya, Nakajima, & Yokoi, 2005).  Previous research has shown that 2OHE1 is anti - 
estrogenic, and as such, has been found to decrease cell proliferation, bind with reduced affinity 
to the estrogen receptor (ER), and gives rise to other anti-estrogenic molecules.  Conversely, 
16OHE1 has exhibited pro–estrogenic properties, such as increasing cell proliferation and 
activating the ER (Seeger, Wallwiener, Kraemer, & Mueck, 2006; Vandewalle & Lefebvre, 
1989; Zhu & Conney, 1998).  It is hypothesized that the ratio of these two catecholestrogens may 
strongly influence breast cancer risk, and that women who metabolize estrogens principally 
through 2OHE1 are at a decreased risk of developing breast cancer, while those who metabolize 
estrogen primarily through 16OHE1 are at an increased risk of developing breast cancer.  
Therefore, one goal of this research was to assess the association of the 2OHE1: 16OHE1 EMR 
and breast cancer risk; as well as to explore the relationships between this ratio and the CYP1B1 
Leu432Val polymorphism, mammographic density, and race.  The aims of this study were: 1) to 
explore the relationship between the urinary 2OHE1:16OHE1 EMR and the role of the CYP1B1 
Leu432Val polymorphism in a case-control population of Caucasian women; 2) to explore the 
relationship between the serum 2OHE1:16OHE1 EMR and mammographic density in a cohort of 
healthy, pre- and postmenopausal African American and Caucasian women; and 3) to determine 
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the 2OHE1:16OHE1 EMR in normal and tumor breast epithelial cell lines derived from African 
American and Caucasian women. 
The results of these analyses will allow us to determine the relationship between the 
2OHE1:16OHE1 EMR and breast cancer risk, while assessing the role the CYP1B1 Leu432Val 
polymorphism plays in this association.  We will also be able to evaluate any racial differences 
that may exist in the 2OHE1:16OHE1 EMR and the factors that many contribute to this ratio, 
which may explain the disparity in incidence and mortality between African American and 
Caucasian women.  Our findings will also add to the body of knowledge regarding 
intracrinology, the local production of hormones, by examining whether racial differences, 
differences in cell type, and estradiol treatment can be detected in culture, providing a new 
methodology in which to evaluate potential breast cancer biomarkers. 
1.1 BACKGROUND AND SIGNIFICANCE 
Breast cancer is defined as, “An uncontrolled growth of cells in the lobules (glands responsible 
for milk production) and ducts (tube-like projections that connect the lobules to the nipples) of 
the breast” (American Cancer Society, 2008c).  Breast cancer has become a significant public 
health challenge due to the complexities in prevention, risk reduction, and appropriate 
intervention methods.  After non-melanoma skin cancer, breast cancer is the most frequently 
diagnosed cancer among women in the United States, accounting for more than one in four 
cancer diagnoses (American Cancer Society, 2007; National Cancer Institute, 2008b).  
Furthermore, breast cancer is the second leading cause of cancer-related mortalities in women, 
4 
 
preceded only by lung cancer (National Cancer Institute, 2008b).  While breast cancer affects 
women of all racial/ethnic groups, the disparity facing African American women presents an 
even greater challenge in the quest to prevent and adequately treat women affected with this 
disease; therefore making the elimination of health disparities in breast cancer a goal of Healthy 
People 2010 (United States Department of Health and Human Services, 2009). 
1.1.1 Incidence, Prevalence, and Mortality 
The Surveillance Epidemiology and End Results (SEER) program reported that the age-adjusted 
breast cancer incidence rate for women of all races in 2006 was 123.8 per 100,000 women.  As 
of January 2006, there were 2,533,193 women living with a history of breast cancer.  This 
included women with active disease, and those with no sign of disease.  The age-adjusted breast 
cancer mortality rate in 2006 was 24.5 per 100,000 women of all racial/ethnic groups.  The 
SEER program also predicts that there will be 192,370 new cases, and 40,170 deaths due breast 
cancer in the year 2009 (Surveillence Epidemiology and End Results, 2009).  When these results 
were stratified by race, African American women had a considerably lower incidence rate when 
compared to Caucasian women, 117.7 versus 127.8 per 100, 000, respectively.  However, the 
mortality rates of African American women were much higher than Caucasian women, 33.0 
versus 23.9 per 100, 000 in 2005 (Surveillence Epidemiology and End Results, 2009). 
Broad surveillance of all cancers began in 1975 to illustrate overall trends in incidence 
rates.  The American Cancer Society (ACS) reported that from 1975 to 1980, the incidence rates 
of breast cancer were relatively stable.  From 1980 to 1987, the incidence of breast cancer 
increased dramatically, 3.7% per year, and in the years from 1987-2001, these rates continued to 
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increase at a nominal 0.5% per year.  Yet, from 2001 to 2004, breast cancer incidence rates 
dropped considerably at a rate of 3.5% per year (American Cancer Society, 2007). 
It is believed that the sudden increase in breast cancer diagnoses that occurred from 1980 
to 1987 was largely due to the development of mammography.  This allowed improved screening 
and increased early detection of impalpable tumors.  The moderate increase observed in the 
1990s indicates the frequent use of mammography, increasing obesity rates, and the use of HRT; 
the latter two being known risk factors for breast cancer.  Nonetheless, the rapid decline in 
incident cases from 2001 to 2004 is likely due to the mass discontinuance of HRT in 2002, after 
the Woman‟s Health Initiative randomized clinical trial was terminated prematurely because 
participants exceeded the expected risk for developing breast cancer (American Cancer Society, 
2007). 
1.1.2 Etiology 
Cancer is defined as a group of more than 100 diseases, in which a single, abnormal cell begins 
to divide without control (Surveillence Epidemiology and End Results, 2009).  This response is 
due to cellular damage, which may occur when a gene, or part of a gene, is deleted, a 
chromosome is translocated, or due to DNA damage that results in a truncated protein.  These 
abnormal cells continue to divide through the expression of oncogenes, and the loss and/or 
mutation of tumor suppressor genes.  Oncogenes are derived from the transformation of proto-
oncogenes, which encode growth factor proteins, and promote normal cell growth when 
appropriately stimulated (Surveillence Epidemiology and End Results, 2009).  The function of 
tumor suppressor genes is to improve the neoplastic process by regulating basic cell function and 
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the cellular environment, controlling cell cycles, cell proliferation, differentiation, apoptosis, and 
DNA repair.  However, when proto-oncogenes are mutated or overly expressed, this activates 
oncogenes, and cells begin to grow in an uncontrolled manner.  When mutated or inactivated, 
tumor suppressor genes lose the ability to prevent this uncontrolled growth (Turnbull & 
Hodgson, 2005).  Cancer cells usually form a tumor, and possess the ability to travel to other 
parts of the body via the bloodstream and lymphatic system, replacing normal tissue (American 
Cancer Society, 2008c).  While scientists work effortlessly to identify the cause of this disease, 
the exact etiology of cancer, and site-specific cancers, such as breast cancer, remains unknown. 
1.1.3 Risk Factors 
Although the etiology of cancer is unknown, researchers have identified several key risk factors 
that have been found to increase an individual‟s risk for developing breast cancer.  Some 
behavioral risk factors include obesity, the use of HRT, OC use, alcohol consumption, and 
physical inactivity.  Some non-modifiable risk factors include increasing age, age at first full-
term birth, early menarche, late menopause, mammographic density, and family history 
(American Cancer Society, 2007; Key et al., 2001).  With the exception of mammographic 
density, alcohol consumption, physical inactivity, and family history of breast cancer, the 
remaining risk factors influence the likelihood of developing breast cancer by increasing one‟s 
lifetime exposure of breast tissue circulating estrogens (American Cancer Society, 2007).  While 
the biological mechanism in which mammographic density influences breast cancer risk is 
unknown, positive associations with other hormonally driven risk factors for breast cancer have 
been observed (e.g. premenopause, late age at first birth, and nulliparity); therefore, it has been 
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postulated that the relationship between mammographic density and breast cancer risk is also 
influence by estrogen exposure (N. Boyd et al., 2009; Vachon, Kuni, Anderson, Anderson, & 
Sellers, 2000).  Moreover, the relationship between breast cancer risk and alcohol consumption is 
also unclear, as several biological mechanisms have been proposed.  It has been reported that 
alcohol consumption may interfere with the function of the essential nutrients of fruits and 
vegetables that are thought to be cancer-protective (Singletary & Gapstur, 2001).  Evidence also 
suggests that the risk of breast cancer related to alcohol consumption may be mediated by 
genetic factors.  Significant gene-environment interactions were found between alcohol 
consumption and two glutathione S-transferase genes (GSTM1 and GSTT1) that play an active 
role in detoxifying both endogenous and exogenous toxic substances (Park et al., 2000).  
Additionally, polymorphisms in genes responsible for alcohol metabolism, specifically, alcohol 
dehydrogenases that are responsible for oxidizing ethanol to acetaldehyde, have been also been 
investigated to assess the association between alcohol and breast cancer risk, yet these results 
have been inconsistent (Boffetta & Hashibe, 2006; Freudenheim et al., 1999; Hines et al., 2000; 
Singletary & Gapstur, 2001).  The risk of breast cancer associated with physical inactivity is 
directly related to the effects of sedentary behavior (e.g., obesity and hormonal and energy 
imbalances), but must be inferred from studies examining the protective effects of physical 
activity on breast cancer risk.  These include maintaining energy and hormonal balance, and 
increasing energy expenditure, as well as weight control (American Cancer Society, 2007; 
National Cancer Institute, 2009). 
Formal linkage analyses of rare families with multiple members with breast cancer have 
proven the existence of an autosomal dominant transmission of breast cancer predisposition.  
These studies have identified two genes, BRCA1 and BRCA2, with variable penetrance as one 
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cause of Heredity Breast Cancer (National Cancer Institute, 2008b).  These genes function as 
tumor suppressors, and are involved in homologous DNA repair, maintaining genomic stability, 
transcriptional regulation, and cell cycle control (Brooker, 2009; National Cancer Institute, 
2008b; Thull & Vogel, 2004).  The Breast Cancer Information Core (BIC) database has 
registered more than 200 germline mutations in BRCA1, and over 100 mutations in BRCA2 that 
are associated with breast cancer susceptibility (Breast Cancer Information Core, 1998). 
BRCA1 is located on chromosome 17q12-21, and contains 24 exons that encode a protein 
of 1,863 amino acids (National Cancer Institute, 2008b; Petrucelli, Daly, Bars-Culver, & 
Feldman, 1998).  It is estimated that the prevalence of BRCA1 mutations in the general 
population is between 1:500 and 1:1000 (Petrucelli et al., 1998).  Malone et al. (2006) conducted 
a population-based case-control study to assess the role of BRCA1 in African Americans and in 
women between the ages of 35 to 64 years.  The authors observed that BRCA1 mutations were 
found in 2.4% of cases when compared to 0.04% of controls.  Among cases, the prevalence of 
BRCA1 mutations decreased with increasing age (p < 0.001), and was twice as frequent in 
Caucasians when compared to African Americans, 2.9% versus 1.4%, respectively (p < 0.05).  
Yet, the frequency of BRCA1 mutations was substantially more common among cases of Jewish 
ancestry, 10.2% (p < 0.001).  The frequency of BRCA1 mutations also varied by family history, 
when comparing those with and without a first-degree relative with breast cancer; 5.6% and 
1.9%, respectively (Malone et al., 2006). 
BRCA2 is located on chromosome 13q12.3, and contains 27 exons that encode 3,418 
amino acids (National Cancer Institute, 2008b).  The prevalence of BRCA2 mutations in the 
general population is unknown, but Malone et al. (2006) found that BRCA2 mutations were more 
frequent among women with a younger age at-onset of breast cancer: 4.0% of cases aged 35 to 
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44 and 1.5% of cases aged 45 to 64 (p = 0.003), respectively (Malone et al., 2006).  When 
examining the frequency of BRCA2 mutations and family history, Malone, et al. (2006) observed 
that cases with three or more relatives with breast cancer, and in those with a diagnosis before 
age 45, had a much higher proportion of BRCA2 mutations, when compared to those with no 
family history (10.7%, p = 0.004; 7.4%, p = 0.002, respectively).  BRCA2 mutations were also 
more common among families with a history of both breast and ovarian cancer (Malone et al., 
2006). 
Germline mutations in BRCA1 and BRCA2 are associated with an estimated 60% lifetime 
risk of developing breast cancer (National Cancer Institute, 2008b).  However, mutations in these 
genes do not account for all hereditary breast cancer cases.  Cancer syndromes, such as Li 
Fraumeni, Cowden Syndrome, Peutz-Jeghers Syndrome, and Ataxia-telangiectasia, all present 
significant risks for developing breast cancer as well (Table 1) (National Cancer Institute, 2008b; 
Thull & Vogel, 2004). 
Nonetheless, investigators have concluded that sporadic cancer predisposition is largely 
polygenic, and occurs as a result of somatic mutations in numerous low-penetrant genes.  It is 
presumed that these low-penetrant genes would exhibit a small effect on breast cancer risk, 
however, in combination with other genetic loci and environmental risk factors, they could 
significantly modify breast cancer risk (National Cancer Institute, 2008b; Thull & Vogel, 2004).  
These genetic alterations are fairly common, and are termed polymorphisms, as the particular 
gene or locus occurs in several “forms” in at least 1% of the population (Table 2) (National 
Cancer Institute, 2008b). 
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Table 1.  Highly Penetrant Cancer Syndromes and Breast Cancer Risk1 
Syndrome Gene(s) Genetic Defect 
Population 
Incidence 
Penetrance 
Lifetime Risk 
of Breast 
Cancer 
Li Fraumeni 
Syndrome 
TP53 
Tumor 
suppression/DNA 
repair 
Rare 90-95% 97% 
Cowden 
Syndrome 
PTEN 
Protein 
phosphatase 
activity 
1/200,000 90-95% 25-50% 
Puetz-Jeghers 
Syndrome 
STK11 
Tumor 
Suppression/DNA 
repair 
1/200,000 95-100% 31% 
Ataxia 
Telangiectasia 
ATM DNA repair 1/30,00 to 1/100,000 100% 52-60% 
Hereditary 
Diffuse Gastric 
Cancer 
CDH1 E-cadherin Unknown/rare 90% 
39% lobular 
breast cancer 
Bloom Syndrome BLM DNA repair Unknown/rare 100% 150-300% 
Werner 
Syndrome 
WRN 
RecQ 
Helicase/DNA 
repair 
~ 1/200,000 90% Unknown 
Xeroderma 
Pigmentosa 
XPA, XPC, 
ERCC, DDB2, 
ERCC4, 
ERCC5, and 
POLH 
DNA repair 1/100,000 100% Unknown 
Nijmegen 
Breakage 
Syndrome 
NBS1 
Nibrin/DNA 
repair 
Rare 100% Unknown 
Fanconi Anemia 
PALB2, BRIP1, 
BRCA2, 
FANCA, 
FANCB, 
FANCC, 
FANCD2, 
FANCE, 
FANCF, 
FANCG, 
FANCI, 
FANCL, 
FANCM 
DNA repair 1/360,000 100% Unknown 
 
                                                 
1 Citations in appendix a 
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Table 2.  Low Penetrance Breast Cancer Susceptible Variants2 
Locus Gene Reference SNP/ Mutation 
10q26 FGFR2 
rs2981582 
rs1219648 
16q12 
TNRC9 
LOC643714 
rs3803662 
rs3803662 
2q35  rs13387042 
5p12 MRPS30 rs10941679 
5q11 
MAP3K1 
MGC33648 
MIER3 
rs889312 
2q33 
CASP8 
TRAK2 (34) 
ALS2CR12 
ALS2CR2 
ALS2CR11 
LOC389286 
LOC729191 
rs1045485 
8q24  rs13281615 
11p15 
LSP1 
TNNT3 
MRPL23 
H19 
LOC728008 
rs3817198 
26q22-q31 CYP17 Promoter T        C (T1931C) 
10q26 CYP19 
Polymorphic (TTTA) 
repeat in intron 5 
C → T in exon 10 
2p22-21 CYP1B1 rs1056836/ Leu432Val 
22q13.1 CYP2D6 
2367delA (A allele;, 
Intron 3 G       A (G1934A) (B 
allele; Del Lys281 (C allele); 
17.5-kb deletion (D allele); 
Frameshift 
Premature stop at residue 544 
19 EDH17B2 Exon 6 A         G (Ser312Gly) 
11q22-q23 PGR 
Alu repeat insertion in intron G 
V660L 
4p15.1 PPARGC1A C1835T; Thr612Met 
15q24.1 CYP1A1 
3801T        C 
3205T        C 
IL462Val 
Thr461Asp 
1p13.3 GSTM1  
22q12.1 CHEK2 
1100delC 
I157T 
IVS2 + 1G        A 
R145W 
S428F 
 
22q11.21 COMT Val158Met 
                                                 
2 Citations in appendix b 
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Epidemiological studies of breast cancer have established that hormonal factors, sex 
hormones in particular, also play a vital role in the etiology of disease (Key et al., 2001).  This 
premise is supported when reviewing the risk factors associated with disease, and confirms that 
the risk of breast cancer is elevated in those with early menarche and late menopause, therefore 
increasing endogenous estrogen exposure.  Furthermore, animal studies have also demonstrated 
that estrogen and progesterone exposure promote the development of some mammary tumors.  
Lastly, increased exogenous hormone exposure in the form of contraceptives and HRT, also 
increases breast cancer risk (European Society of Human Reproduction and Embryology, 2004). 
Another significant contributor to breast cancer risk is mammographic density.  
Mammographic density is a heritable measure of breast composition, and is the proportion of 
fibroglandular elements (i.e., stroma and epithelium) to total breast area (N. Boyd et al., 2009; 
Dite et al., 2008; Vachon et al., 2000).  Breasts that are composed of 75% dense tissue are 
classified as being “mammographically dense,” while those composed exclusively of fat, are 
identified as having “no measurable dense tissue” (Haiman et al., 2003).  Furthermore, numerous 
studies have reported that women with “mammographically dense” breast have a four to six 
times relative risk of developing breast cancer (Aiello et al., 2005; N. Boyd et al., 2009; Tamimi, 
Byrne, Colditz, & Hankinson, 2007; Tamimi, Hankinson, Colditz, & Byrne, 2005; Warren, 2004; 
Warren et al., 2006; Woolcott et al., 2009).  The literature suggests that mammographic density 
decreases with age, pregnancy, menopause, and increasing BMI (N. Boyd et al., 2009; N. F. 
Boyd et al., 2009).  Mammographic density has also been shown to be altered by exogenous 
hormone use and menstruation, making it a useful biomarker of risk, as it is presumed that a 
change in density may reflect a change in breast cancer risk (Warren, 2004). 
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1.1.4 Prevention and Screening 
In an effort to reduce the burden of breast cancer, the National Cancer Institute (NCI) and the 
ACS recommend several screening options.  The most commonly used screening methods to 
detect breast cancer include: 
1. Breast Self Exam: Physical, self examination of the breast, 
recommended for women in their 20‟s. 
2. Clinical Breast Exam: Performed by a physician or other health 
professional, which consist of a careful physical examination of the 
breast and area under the arm for lumps or other unusual findings.  
This is recommended for women in their 20‟s and 30‟s as part of a 
regular health exam. 
3. Mammograms: X-ray of the breast capable of detecting impalpable 
tumors, and ductal carcinoma in situ (abnormal cells in the lining of 
the breast duct).  Mammograms are recommended for women over the 
age of 40 every one to two years (American Cancer Society, 2008b; 
National Cancer Institute, 2008a). 
1.2 CLASSIC ENDOCRINOLOGY 
The endocrine system is one of the 11 major organ systems of the body that consists of a 
compilation of integrated glands and organs, such as: 
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  Hypothalamus; 
 Pituitary Gland; 
 Pineal Gland; 
 Thyroid Gland; 
o Parathyroid Gland; 
 Adrenal Gland; 
 Pancreas; 
 Ovaries; and 
 Testes (Foster, 2008; Surveillance Epidemiology and End Results, 
2009). 
These glands and organs function in the release of biologically active hormones, and play a vital 
role in the body‟s growth, metabolism, and sexual development.  The hormones secreted by this 
system are transported into the blood, where they then travel to their target tissues, where 
specific receptors await to receive them (Foster, 2008). 
Hormones are classified into two groups, peptides and steroid hormones.  Peptide 
hormones are generally produced as large proteins, and are synthesized by the anterior pituitary 
gland, thyroid gland, parathyroid gland, or pancreas,  whereas, steroid hormones are produced by 
the adrenal gland, ovary, or testis (Kletter, 2008). 
There are five major classes of steroid hormones: progestagens, glucocorticoids, 
mineralcorticoids, androgens, and estrogens.  Each of these steroid hormones regulates gene 
expression, by binding and activating receptor molecules that function as transcription factors 
(Berg, Tymoczko, & Stryer, 2002).  For this study, we will only focus on the direct synthesis and 
action of estrogens. 
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Estrogen biosynthesis is catalyzed by the Cytochrome P450 superfamily of genes that 
encode a number of enzymes that are directly involved in drug and steroid metabolism (Genetics 
Home Reference, 2006; Nebert & Russell, 2002).  The primary site for estrogen biosynthesis is 
in the theca cells of the ovary.  The synthesis of estrogen starts with the formation of cholesterol, 
a 27-carbon lipid molecule that is a vital component of the plasma membrane (Figure 1) (Albert 
et al., 2002; Berg et al., 2002).  The next step involves the removal of a 6-carbon unit to form 
pregnenolone. This process is carried out through the CYP11A1 gene, which encodes the enzyme 
cholesterol desmolase, otherwise known as P450 side chain cleavage (P450scc), and 
adrenocorticotrophic hormone (ACTH), a polypeptide synthesized by the anterior pituitary gland 
(Berg et al., 2002; GeneCards, 2008).  From pregnenolone, progesterone is derived via the 
catalyzation of 3β-hydoxy steroid dehydrogenase (Burger, 2002; Olson, Bandera, & Orlow, 
2007).  Then, an intermediate progesterone is produced, 17α-Hydroxyprogesterone, from the 
hydroxylation of C-17 of progesterone, through the 17α hydroxylase enzyme coded by the 
CYP17A1 gene.  Another enzyme of the CYP17A1 gene, 17/20 lyase, a derivative of 17α 
hydroxylase, catalyzes the cleavage of carbons 20 and 21 to yield androstenedione.  From 
androstenedione, two products are formed: 
1. Testosterone, via the 17β-hydroxy steroid dehydrogenase enzyme; and 
2. Estrone (an estrogen), after cleavage of carbon 20, and the aromatase 
activity encoded by the CYP19A1 gene. 
Utilizing the same aromatase activity of CYP19A1, testosterone produces another 
estrogen, estradiol (Berg et al., 2002; Burger, 2002; Olson et al., 2007). 
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Figure 1.  Classic Endocrinology and Associated Genes3 
 
There are three naturally occurring types of estrogen: estradiol, estrone, and estriol.  
Estradiol (17β-estradiol), the parent hormone, is the most abundant of the three, being present in 
both males and females (Johnson, 2008; Marieb, 2009).  The metabolism of estradiol takes place 
in the liver, and is essentially the same in both sexes (Mueck et al., 2002; Zhu & Conney, 1998).  
Estradiol is metabolized almost exclusively through oxidation.  The first step takes place at 
                                                 
3 Adapted from “Androgen Production in Women,” 2002, Fertility and Sterility, 77, p. S3-S5.  Copyright 2002 by American 
Society for Reproductive Medicine. 
 
Adapted from “Biochemistry”, 2002, The Biosynthesis of Membrane Lipids and Steroids, p. 735-736.  Copyright 2002 by W.H. 
Freeman and Company. 
 
Adapted from “Variants in estrogen biosynthesis genes, sex steroid hormone levels, and endometrial cancer: a HuGE review,” 
2007, American Journal of Epidemiology, p. 235-245.  Copyright 2006 by the Johns Hopkins Bloomberg School of Public 
Health. 
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position C-17, and results in the oxidation of estradiol to estrone by 17β-hydroxysteriod 
dehydrogenase.  This step is reversible, but the formation of estrone is favored.  At this point, 
further metabolism occurs via two separate pathways (Mueck et al., 2002).  The A-ring of 
estrone is hydroxylated and produces two catechol estrogens, 2-hydroxyestrone (2OHE1) and 4-
hydroxyestrone (4OHE1); while the D-ring is hydroxylated to form one catechol estrogen, 16α-
hydroxyestrone (16OHE1), which is later metabolized to estriol (Clemons & Goss, 2001; Mueck 
et al., 2002).  These two pathways are formed by two separate enzyme systems; the A-ring is 
hydroxylated by CYP1A1, CYP1A2, and CYP1B1 genes, while the D-ring is hydroxylated by 
CYP1B1, CYP2C19, CYP1A1, and CYP3A5 (Badawi et al., 2001; Cribb et al., 2006; Tsuchiya et 
al., 2005).  Once formed, these metabolites, 2OHE1, 4OHE1, 16OHE1, and estriol, can no longer 
be reduced back to estrone, and are the most active in the human metabolic process (Figure 2) 
(Mueck et al., 2002). 
Each estrogen metabolite is biologically distinct, and has various functions.  Estriol is the 
primary circulating estrogen during pregnancy, and experiences an exponential increase after 
thirty-four weeks gestation.  This surge has been observed at two to four weeks before the onset 
of term labor, while the absence of estriol was noted among women who presented for induction 
at forty-two weeks gestation. These results support the theory that estriol is important in the 
initiation of labor in humans (Yeast & Lu, 2007). 
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Figure 2.  Estradiol Catabolism4 
 
The remaining metabolites, 2OHE1, 16OHE1, and 4OHE1 have been implicated as 
markers of breast cancer risk.  Nevertheless, 4OHE1 has been reported to be less stable than 
2OHE1 and 16OHE1 (Mueck & Seeger, 2007).  The remaining metabolites, 2OHE1, 16OHE1, and 
                                                 
4 Adapted from “Estradiol Metabolism and Malignant Disease,” 2002, Maturitas, 43, p. 1-10.  Copyright 2002 by Elsevier 
Science Ireland Ltd.  Adapted with permission of the author. 
 
Adapted from “Oxidative Metabolism of Estradiol,” 1960, The Journal of Biological Chemistry, 11, p. 3104-3107.  Printed in the 
USA.   
 
Adapted from “Cytochrome P450-mediated metabolism of estrogens and its regulation in human,” 2005, Cancer Letters, 227, p. 
115-124.  Copyright 2005 Elsevier Science Ireland Ltd. 
 
Adapted from “Role of Polymorphic Human Cytochrome P450 Enzymes in Estrone Oxidation,” 2006, Cancer Epidemiology, 
Biomakers, &Prevention , 15(3), p. 551-558.  Copyright 2006 American Association for Cancer Research. 
 
Adapted from “Role of Human Cytochrome P450 1A1, 1A2, 1B1, and 3A4 in the 2-, 4-, and 16α-Hydroxylation of 17β-
Estradiol,” 2001, Metabolism, 50(9), p. 1001-1003.  Copyright 2001 W.B. Saunders Company. 
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4OHE1 have been implicated as markers of breast cancer risk.  Nevertheless, 4OHE1 has been 
reported to be less stable than 2OHE1 and 16OHE1 (Zhu & Conney, 1998). 
Furthermore, less than 5% of estrogens become 4OHE1 (Service, 1998).  It is for this reason we 
have chosen to focus our attention on 2OHE1 and 16OHE1. 
2OHE1 and 16OHE1 have contrasting biological properties (Lord et al., 2002).  2OHE1 is 
capable of binding to the estrogen receptor (ER), but with reduced binding affinity (Zhu & 
Conney, 1998).  This anti-estrogenic metabolite has been shown to decrease cell proliferation by 
20 to 30% in cultured breast cancer cell lines (Vandewalle & Lefebvre, 1989).  This anti-
estrogenic metabolite has been shown to decrease cell proliferation by 20 to 30% in cultured 
breast cancer cell lines (Zhu & Conney, 1998).  On the other hand, 16OHE1 is a potent estrogenic 
molecule that functions by activating the ER, and increases proliferation of cultured breast 
cancer cells by 40% (Seeger et al., 2006; Zhu & Conney, 1998).  In cells treated with 16OHE1, 
there was also a 30% to 50% increase in BCL-2, an anti-apoptotic marker, and a 30% to 40% 
decrease in Cytochome C, a pro-apoptotic marker (Seeger et al., 2006). 
The catabolism of 2OHE1 produces other anti-estrogenic metabolites, whereas 16OHE1 is 
strongly estrogenic, and is believed to be a potential carcinogen.  Therefore, the ratio of 2OHE1 
and 16OHE1 regulates the proportion of anti-estrogenic molecules to estrogenic ones.  Thus, it is 
hypothesized that women who metabolize estrogen primarily through the 2OHE1 pathway have a 
lower risk of developing breast cancer, while those who metabolize estrogens primarily through 
the 16OHE1 pathway are at an increased risk of developing breast cancer. 
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1.3 ESTROGENS AND BREAST CANCER 
The association between estrogens and breast cancer risk was first demonstrated by Beatson in 
the late 19th century. He discovered the growth-stimulating properties of estrogen on breast 
tumors, and that tumor growth could be reduced by the removal of the ovaries (T. H. Lippert, 
Seeger, & Mueck, 2000).  Given that estrogens are released directly into the bloodstream, it is 
not surprising that many studies have observed an association between elevated blood-estrogen 
levels and breast cancer risk.  This finding is prominent in postmenopausal women, and is likely 
due to increased body weight, as aging and menopause are associated with weight gain, central 
adiposity, and physical inactivity, all risk factors for breast cancer (Baglietto et al., 2008; Gruber, 
Tschugguel, Schneeberger, & Huber, 2002; Yager & Davidson, 2006).  BMI has also been 
reported as being associated with breast cancer risk among postmenopausal women.  As little to 
no estrogen is synthesized in the ovaries, androgens, estrogens precursor molecules, must be 
converted to estrogens in extragonadal tissue, such as the liver, muscle, and skin; however, the 
majority of estrogens are produced in adipose tissue (Baglietto et al., 2008; Clemons & Goss, 
2001).  It is for this reason that obesity is a major risk factor for postmenopausal women.  
Consequently, obese postmenopausal women have a higher risk of developing breast cancer, 
than do non-obese postmenopausal women (Clemons & Goss, 2001).  Other contributors to the 
association between elevated blood-estrogens and breast cancer risk include the large number of 
risk factors that contribute to the cumulative exposure of estrogen (e.g., OC use, HRT use, age at 
menarche, age at first full-term birth, and age at menopause) (Yager & Davidson, 2006).  
However, this association in premenopausal women is unfounded, as there is a lack of sufficient 
evidence to draw a definitive conclusion. 
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Although breast cancer in young, premenopausal patients seem to be more aggressive, 
poorly differentiated, exhibit rapid proliferation and vascularization, are estrogen receptor (ER) 
and progresterone receptor (PR) negative, and has a higher frequency of bone micrometasteses, 
few studies have addressed the association of circulating sex steroids in these women (Aebi & 
Pagani, 2007; Hankinson & Eliassen, 2007).  This is due in large part to fluctuating hormone 
levels during the menstrual cycle (Hankinson & Eliassen, 2007).  However, analyses that have 
assessed this association are plagued by small sample size (Eliassen et al., 2006; Hankinson & 
Eliassen, 2007).  In a recent study using the Nurse‟s Health Study II data, Eliassen, et al. (2006) 
found that women with high total follicular estradiol and free follicular estradiol concentrations 
demonstrated a significantly increased risk of breast cancer (RR for total follicular estrogen 
concentrations = 2.1, 95% CI 1.3 – 4.1, p for trend = 0.08; RR for free follicular estradiol = 2.4, 
95% CI 1.3 – 4.5, p for trend = 0.01) (Eliassen et al., 2006). 
Despite the disparity facing African American women, endogenous hormone 
concentrations in this population are rarely studied.  It is known that African American women 
age 40 and older have a lower risk of developing breast cancer compared to Caucasian women.  
Yet, the risk is much greater for African American women under the age of 40, although their 
mortality rate exceeds that of Caucasians at every age (American Cancer Society, 2008a).  
Women of African descent are more likely to be diagnosed with breast cancer at a more 
advanced stage (which includes some stage III and stage IV tumors), have larger, estrogen-
negative, high grade tumors, as well as lymph node involvement; all of which are poor 
prognostic predictors of survival (Breastcancer.org, 2008; Chlebowski et al., 2005; Curtis, Quale, 
Haggstrom, & Bindman-Smith, 2008).  However, the ACS reported that the proportion of 
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African Americans that underwent breast cancer screening in 2004 nearly matched that of 
Caucasians (Table 3) (American Cancer Society, 2008a). 
Table 3.  Use of Breast Cancer Screening Examination 
Breast Cancer Screening 
Method 
African Americans Caucasians 
Mammogram 59.4 58.6 
Clinical Breast Exam 64.3 65.6 
Mammogram & Clinical Breast 
Exam 
51.2 52.2 
 
While the reasons behind these differences remain unknown, many have suggested that 
socioeconomic factors, such as a lack of access to health care and inadequate treatment after 
diagnosis are possible explanations.  Nonetheless, Wojcik, Spinks, & Optenberg (1998) 
conducted a retrospective study of breast cancer patients diagnosed and treated in the United 
States military equal-access medical care system (United States Department of Defense), to 
evaluate survival differences between African American and Caucasian women.  The authors 
observed that while African American participants fared better than African Americans 
nationally, participants still suffered higher mortality rates than did Caucasian participants 
(24.77% versus 18.09%) (Wojcik, Spinks, & Optenberg, 1998).  These results were duplicated in 
a more recent study that also indicated that the mortality difference between African Americans 
and Caucasians was increasing in the United States Department of Defense healthcare system 
(Jatoi, Becher, & Leake, 2003).  Therefore, access to healthcare, or a lack thereof, does not 
explain the mortality disparity facing African American women.  Yet, when Pinheiro et al. 
(2005), assessed potential racial differences in premenopausal hormone concentrations, the 
authors observed that African Americans expressed 18% higher estradiol levels (170 pg/ml 
versus 144 pg/ml; p < 0.01), 17% higher free estradiol levels (2.1 pg/ml versus 1.8 pg/ml; p < 
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0.01), and 11% lower sex-hormone binding globulin (63 nmol/L versus 71 nmol/L; p = 0.05) 
when compared to Caucasians (Pinheiro, Holmes, Pollak, Barbieri, & Hankinson, 2005).  While 
more research is needed in this area, findings such as these may assist in explaining the 
differences in breast cancer morbidity and mortality in African American populations. 
Estrogens have also been examined in relation to mammographic density; as increases in 
mammographic density increase breast cancer risk.  It is believed that the risk of developing 
breast cancer in relation to mammographic density may be due to the cumulative exposure of 
breast stroma and epithelium to sex hormones (N. Boyd et al., 2009).  Nonetheless, few studies 
have addressed the effects of endogenous estrogens on mammographic density, and focus 
primarily on the effects of exogenous hormone use, specifically postmenopausal hormone use.  
However, these studies all demonstrate that hormone therapy consisting of estrogen and 
progesterone increases mammographic density (Boyd et al., 2005; Vachon et al., 2000; Warren, 
2004; Wellejus et al., 2005; Ziv et al., 2004).  In fact, in a cross sectional analysis of 
postmenopausal women, not using HRT, a statistically significant positive association between 
percent mammographic density and serum levels of estrone (p = 0.013), estradiol (p = 0.008), 
and bioavailable estradiol (p = 0.017) was observed (Greendale et al., 2005).  Conversely, the 
anti-estrogen, Tamoxifen, has been reported to decrease mammographic density (Ziv et al., 
2004).  One study sought to compare the effects of the ER modulator, Raloxifene, and a low dose 
of transdermal estradiol on mammographic density in a group of postmenopausal women.  The 
authors observed an increase in dense area in both groups, however, the increase by estradiol 
obtained statistical significance (Raloxifene: baseline – 0.16, 2 year. follow-up – 0.18; Estradiol: 
baseline – 0.16, 2 year. follow-up – 0.2, p < 0.05) (Nielsen et al., 2009). 
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Variations in mammographic density have also been assessed in various racial/ethnic 
groups, to determine if these differences account for the disparity in breast cancer risk 
experienced by minority populations.  However, the results of these studies are inconsistent.  
Some studies report that mammographic density does not vary by race, while others cite African 
Americans as having significantly higher or lower breast density when compared to Caucasian or 
Asian American women.  In fact, one study found that after adjusting for BMI, African 
Americans were more likely to have a higher breast density when compared to Caucasian women 
(OR = 1.4; 95% CI 1.2 – 1.6).  This association became stronger after adjusting for BMI, 
reproductive and hormonal factors, in women age 65 and younger (ages ≤ 45 years: OR = 1.7; 
95% CI 1.2 – 2.3; ages 46 – 55 years: OR = 1.3; 95% CI 1.0 – 1.7; ages 56 – 65 years: OR = 1.7; 
95% CI 1.2 – 2.3) when compared to women age 65 and over (OR = 1.1; 95% CI 0.7 – 1.6) (El-
Bastawissi, White, Mandelson, & Taplin, 2001).  Conversely, in a study by del Carmen, Hughes, 
Halpern, et al. (2003), African American women had a much lower mammographic density 
compared to Caucasian, Latina, and Asian American women (African American: 2.43; 
Caucasian: 2.69; Latina: 2.65; and Asian American: 3.09).  This finding persisted, even after 
adjusting for age, BMI, and variations in measuring mammographic density (African American 
adjusted mean density: 2.54; Caucasian adjusted mean density: 2.66; p = 0.0006; Latina adjusted 
mean density: 2.67; p = 0.0139; Asian American adjusted mean density: 2.79; p = 0.0372) (del 
Carmen et al., 2003).  The results presented here further demonstrate the complexity involved in 
understanding the underlying mechanisms of the racial/ethnic differences in breast cancer risk, 
and also exhibit the necessity for further research. 
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1.4 INTRACRINOLOGY 
As previously mentioned, hormones are secreted via the organs and glands of the endocrine 
system.  They are then transported through the blood, where they act on their target tissues to 
elicit a response from specific receptors.  As the systematic name implies, this type of hormone 
action is called, “endocrine” (Sasano, Suzuki, Miki, & Moriya, 2008).  However, several studies 
have demonstrated the ability of peripheral organs to synthesize their own estrogen.  In fact, 
approximately 75% of estrogens in premenopausal women, and nearly 100% of the estrogens 
produced in postmenopausal women, are synthesized in extragondal tissues, utilizing circulating 
androgens.  This local production of hormone is termed, “intracrine,” as the hormone derived 
exerts its effects within the cells in which it is produced (Foster, 2008; Sasano et al., 2008). 
The production of estrogens is tissue-specific.  The ovary, which is the primary source of 
estrogen in premenopausal women, produces mostly estradiol, while the placenta produces 
estriol, and adipose tissue generates estrone.  Estrone is the predominant form of estrogen in 
postmenopausal women, and the parent substance of 2OHE1 and 16OHE1 (Miettinen, Isomaa, 
Peltoketo, Ghosh, & Vihko, 2000; Mueck et al., 2002; Sasano, Suzuki, Nakata, & Moriya, 2006; 
Simpson et al., 1994).  Although the main circulating estrogen in postmenopausal women is 
estrone, it exists primarily in its sulfated form as estrone sulfate (E1S), via estrogen 
sulfotransferase (EST) (Miettinen et al., 2000; Sasano et al., 2006; Suzuki, Moriya, Ishida, 
Ohuchi, & Sasano, 2003).  EST belongs to a superfamily of steroid sulfotransferases that 
function in converting estrogens to biologically inactive, estrogen sulfates.  E1S is then 
converted to estrone, via steroid sulfotransferase (STS) (Pasqualini & Chetrite, 1999; Sasano et 
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al., 2006).  This pathway is entitled the “sulfatase pathway”(Figure 3) (Pasqualini & Chetrite, 
1999). 
As mentioned previously, the “aromatase pathway” catalyzes the conversion of 
androgens to estrogens in the ovary.  Yet, this pathway is also present in breast tissue.  In fact, 
immunolocalization revealed aromatase activity in the epithelial cells of the ducts of the terminal 
ductal lobular units (TDLU) of normal breast tissue.  In situ hybridization also revealed 
aromatase mRNA in the adjacent stroma cells of the TDLU, as well as in epithelial cells lining 
cysts, and in the stroma cells of the parenchyma outside of the TDLU.  Furthermore, aromatase 
activity was observed in the cytoplasm of epithelial cells and in the adjacent stroma cells of 
breast tumor tissue (Brodie, Lu, & Nakamura, 1997).  Quantitatively, aromatase activity has been 
detected in more than 70% of breast tumors (Miettinen et al., 2000; Suzuki et al., 2003).  When 
compared to non-malignant tissue, malignant ones expressed significantly greater levels of 
aromatase mRNA (Suzuki et al., 2003). 
However, STS activity has been detected in 90% of breast tumors, in contrast to 
aromatase activity, that is expressed in only 70% of tumors (Foster, 2008; Suzuki et al., 2003).  
This increased activity could potentially result in a 10 fold greater production of estrone via the 
sulfatase pathway rather than the aromatase pathway in breast tissue, leading to a greater 
generation of 2OHE1 and 16OHE1.  Furthermore, Real Time-Polymerase Chain Reaction (RT-
PCR) assays have observed significantly larger amounts of STS activity in breast cancer tissue 
than in normal breast (Foster, 2008).  Considering the evidence presented, EST and STS play 
vital roles in maintaining biologically active estrogens in tissue (Sasano et al., 2008). 
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Figure 3.  Intracrinology5 
                                                 
5 Adapted from “New Developments in Intracrinology of Human Breast Cancer,” 2009, Steroid Enzymes and Cancer, 1155, p. 76-79. Copyright 2009 by New York Academy of 
Sciences. 
 
Adapted from “Intracrine Mechanism of Estrogen Synthesis in Breast Cancer,” 2003, Biomedicine & Pharmacotherapy, 57, p. 460-462.  Copyright 2003 by Éditions Scientifiques 
et Médicales Elesevier SAS. 
 
Adapted from “Intracrinology of Estrogens and Androgens in Breast Carcinoma,” 2008, Journal of Steroid Biochemistry & Molecular Biology, 108, p. 181-185.  Copyright 2007 
Elsevier Ltd. 
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Endocrinology and Intracrinology systems operate using two separate mechanisms of 
action.  In classical endocrinology, hormones are released into the blood to act on target tissues, 
therefore increasing plasma concentrations, and influencing the biological effects of hormone-
dependent tissues (Foster, 2008).  However, only a small portion of the hormones produced are 
actually utilized in the target tissues.  The large majority of hormones produced in this fashion, 
are metabolized to biologically inactive forms.  On the other hand, the intracrine system requires 
only modest amounts of hormones to elicit a maximum effect.  Therefore, this system of 
hormone action is much more efficient in the development of hormone-dependent malignancies 
(Foster, 2008; Sasano et al., 2008). 
1.5 CYTOCHROME P450 1B1 
The Cytochrome P450 is a superfamily of membrane–proteins that consists of 57 genes.  These 
genes encode enzymes that function in the metabolism of drugs, foreign chemicals, arachidonic 
acid and eicosanoids, cholesterol metabolism, bile acid biosynthesis, steroid synthesis and 
metabolism, Vitamin D3 synthesis and metabolism, and retinoic acid hydroxylation (Nebert & 
Russell, 2002).  The proteins of the Cytochrome P450 (CYP) family are arranged into families 
and subfamilies, based on the percentage of comparable amino acid sequence characteristics.  
Cytochromes that have greater than or equal to 40% of the same amino acid characteristics are 
assigned to one group that is denoted by an Arabic numeral.  Then, those that share greater than 
or equal to 55% of the same amino acid characteristics are further arranged into subfamilies that 
are denoted by a letter.  For example, sterol 27-hydroxylase and Vitamin D324-hydroxylase both 
belong to the CYP27 family because they share greater than or equal to 40% of the same amino 
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acid characteristics.  But, sterol 27-hydroxylase is further classified into the CYP27A subfamily, 
while Vitamin D324-hydroxylase belongs to the CYP27B subfamily, as these two enzymes do not 
share greater than or equal to 55% of the same amino acid characteristics.  Moreover, if another 
enzyme(s) was found to have greater than or equal to 55% of the same amino acid characteristics 
as sterol 27-hydroxylase and Vitamin D324-hydroxylase, these enzymes would be further 
classified as CYP27A2 and CYP27B2, and so on (Nebert & Russell, 2002).  There are currently 
more than 270 CYP gene families, yet for this review, we will only focus on CYP1B1. 
Cytochrome P450 1B1 (CYP1B1) maps to chromosome 2p22-p21, and consists of three 
exons and two introns.  This gene is expressed in monocytes, macrophages, and in other 
extrahepatic organs, such as the kidney, prostate, uterus, ovary, and breast. CYP1B1 is regulated 
by the aryl hydrocarbon receptor, a cytosolic transcription factor that is activated by polycyclic 
aromatic hydrocarbons, and dioxin-like compounds.  CYP1B1 can activate several carcinogens, 
such as arylenes, nitrosamines, and arylamines, all of which can cause DNA damage (Beuten et 
al., 2008; Ingelman-Sundberg, 2004; Singh et al., 2008; Wenzlaff et al., 2005). 
There are several variants of this gene, but the most common is a C→G transversion at 
position 1666 in exon 3, the heme-binding domain of the gene, which is critical to its catalytic 
function. This change results in an amino acid substitution of leucine (Leu) to valine (Val) at 
codon 432 (Paracchini et al., 2007).  According to Hapmap data, the frequency of the C allele is 
0.867 among Han Chinese, 0.909 among Japanese, 0.15 among West African, and 0.558 among 
Caucasian populations (International HapMap Project, 2009). 
CYP1B1 is highly involved in estradiol metabolism.  This gene has been reported as 
being responsible for the hydroxylation of estrone at both C-2 and C-16 positions, leading to the 
formation of 2OHE1 and 16OHE1 (Badawi et al., 2001; Cribb et al., 2006; Lord et al., 2002; 
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Tsuchiya et al., 2005).  As mentioned previously, 2OHE1 is anti-estrogenic, while 16OHE1 is a 
potent estrogenic molecule, and it is believed that women who metabolize estrogen principally 
through the C-16 pathway, experience an increased risk for developing breast cancer.  This 
evidence suggests that alterations in the CYP1B1 genotype could influence breast cancer risk.  In 
fact, the Leu432Val polymorphism has been demonstrated to be associated with breast cancer 
risk. 
In a meta and pooled analysis by Paracchini, Raimondi, Gram, et al. (2007), the authors 
observed racial, as well as age differences in the association between the CYP1B1 Leu432Val 
polymorphism and breast cancer risk.  A possible association between the CYP1B1 Leu432Val 
polymorphism and breast cancer risk was also found, but only among Caucasians.  The results of 
this subpopulation also revealed a significant age effect, with an increased risk of breast cancer 
occurring between the ages of 45 and 59 years.  Yet, the observed risk was much lower for both 
younger and older women.  However, this effect was not seen among Asians, while a possible 
negative association was found among African American or mixed populations (Paracchini et al., 
2007). 
In a rather large population study consisting of 1,521 breast cancer cases and 1,498 
controls, a significant association was found among the CYP1B1 Leu432Val polymorphism and 
breast cancer risk among postmenopausal women using HRT.  The authors hypothesized that the 
effect of the CYP1B1 genotype would be more pronounced among long-term users (≥ 4 years) of 
hormones.  In fact, participants who expressed the homozygous variant genotype and who 
reported using HRT for ≥ 4 years, were at a greater risk of developing breast cancer, when 
compared to other postmenopausal women who reported using hormone therapy for ≥ 4 years, 
but did not carry this genotype (OR 2.0; 95% CI 1.1 – 3.5) (Rylander-Rudqvist et al., 2003). 
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A case-control study conducted in Turkey by Kocabas et al. (2002) assessed the 
association of the CYP1B1 Leu432Val polymorphism and breast cancer risk.  Utilizing 84 breast 
cancer patients and 103 controls matched for age, time of blood donation, and menopausal status, 
the authors found that the presence of the valine allele was associated with a significantly 
increased susceptibility of breast cancer.  The adjusted odds ratio for age, age at menopause, age 
at first full term pregnancy, BMI, and smoking status was 2.32 (95% CI 1.26 - 4.25; p = 0.007).  
The authors also observed that the CYP1B1 genotype was related to breast cancer among women 
with a BMI greater than 24 kg/m2 (adjusted OR =  2.78; 95% CI 1.36 - 5.62; p = 0.005) 
(Kocabas, Sardas, Cholerton, Daly, & Karakaya, 2002). 
To date, only one study has been identified that examined the association between the 
CYP1B1 Leu432Val polymorphism and the 2OHE1:16OHE1 EMR.  Paracchini et al (2005) 
assessed this relationship in 150 healthy men and premenopausal women, and observed that the 
presence of the valine allele was associated with an increased urinary 2OHE1:16OHE1 EMR 
among Caucasian women (CYP1B1 Val/Val = 1.95 ±. 1.06; CYP1B1 Val/Leu = 2.08 ± 1.06; 
CYP1B1 Leu/Leu = 2.55 ± 1.37) (Paracchini et al., 2005).  While these results have elucidated 
significant genotype-phenotype correlations, they also emphasize the need for more definitive 
studies verifying the association between the 2OHE1:16OHE1 ratio and the CYP1B1 Leu432Val, 
and their relationship to breast cancer risk. 
1.6 SUMMARY AND CONCLUSIONS 
The role of estrogens and the 2OHE1:16OHE1 EMR in the development and progression of 
breast cancer has long been established.  However, this association has rarely been investigated 
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in relation to the CYP1B1 Leu432Val polymorphism, mammographic density, and race.  
Nonetheless, recent evidence has found an association between the CYP1B1 Leu432Val 
genotype and breast cancer, thereby suggesting that presence of the variant allele may mediate 
this risk.  While the relationship between this genotype and the 2OHE1:16OHE1 EMR has not 
been readily examined, a significant association has been observed, and implies that the CYP1B1 
Leu432Val genotype may alter breast cancer risk through variations in the 2OHE1:16OHE1 
EMR. 
Thus far, the literature presents very little evidence regarding the 2OHE1:16OHE1 EMR 
by race, although some studies have investigated variations in mammographic density and, to our 
knowledge, only one study has examined differences in endogenous estrogen levels by race.  
However, the results of these studies are inconsistent, and need to be confirmed.  Given the 
significant disparity in breast cancer morbidity and mortality between African American and 
Caucasian women, further research is warranted to identify a possible biological explanation for 
this difference. 
Since evidence now suggests that the estrogens produced locally are capable of exerting 
maximum effects, with only modest quantities, it is of particular interest to examine 
concentrations of the 2OHE1:16OHE1 EMR in vitro.  With an incomplete understanding of the 
etiology of disease, but an established relationship between cumulative estrogen exposure and 
breast cancer risk, it is feasible to conclude that 2OHE1:16OHE1 EMR concentrations in breast 
tissue may directly affect breast cancer risk.  Furthermore, when taking race into account, 
investigations of this level may reveal more absolute evidence of differences in estrogen 
exposure and metabolism by race. 
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Breast cancer is a complex disease that affects all women.  Although the overall mortality 
rate has declined in recent years, more research is needed to significantly improve current 
treatment and prevention methods that are sufficient for all women.  Therefore, this study has 
significant implications for public health, as the overall goal of this research is to identify a 
possible biological explanation for the disparity in breast cancer between African American and 
Caucasian women.  Furthermore, this study seeks to confirm the relationship between the 
CYP1B1 Leu432Val polymorphism and the 2OHE1:16OHE1 EMR, which could lead to the 
identification of high risk populations.  Additionally, the relationships between the 
2OHE1:16OHE1 EMR, mammographic density, and race were also examined.  As the biological 
mechanism by which mammographic density affects breast cancer risk is unknown, and the risk 
associated with mammographic density is significantly greater than the associated risk of all 
other clinical risk factors, this investigation serves to determine if the 2OHE1:16OHE1 EMR can 
be utilized to explain variations in mammographic density, and if this relationship differs by 
race.  Lastly, this study seeks to determine if 2OHE1:16OHE1 EMR concentrations can be 
assayed in vitro, and if this ratio is altered by additional estrogen exposure and cell type.  These 
results will provide a better understanding of the etiology of disease, as the 2OHE1:16OHE1 
EMR was assayed directly from breast tissue. 
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2.0  SPECIFIC AIMS 
Again, the objective of this study was to explore some of the relationships found between the 
2OHE1:16OHE1 EMR, the CYP1B1 Leu432Val polymorphism, mammographic density, race, 
and breast cancer risk.  This goal was addressed in three manuscripts, each designed to satisfy 
the following specific aims. 
The Effect of a CYP1B1 Polymorphism on the2OHE1:16OHE1 Estrogen Metabolite Ratio and 
Breast Cancer Risk 
Specific Aim I:  To explore the relationship between the urinary 2OHE1:16OHE1 EMR and the 
role of the CYP1B1 Leu432Val polymorphism in a case-control population of Caucasian women.  
Recent evidence has found an association between the CYP1B1 Leu432Val genotype and 
the urinary 2OHE1:16OHE1 EMR, suggesting that the presence of the variant allele may mediate 
breast cancer risk.  We hypothesize a negative relationship will be observed when evaluating the 
2OHE1:16OHE1 EMR and breast cancer risk, as the evidence suggest a low 2OHE1:16OHE1 
EMR increases breast cancer risk.  Moreover, we also hypothesize that a negative relationship 
will be observed when assessing the association of the CYP1B1 Leu432Val and the 
2OHE1:16OHE1 EMR.  This polymorphism has been reported as being associated with the 
urinary 2OHE1:16OHE1 EMR and the presence of the variant allele has been reported to be 
associated with elevated breast cancer risk.  Therefore, we believe that the Leu432Val 
polymorphism will be negatively associated with the 2OHE1:16OHE1 EMR. 
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The 2OHE1:16OE1 Estrogen Metabolite Ratio, Mammographic Density, and Race: 
Examining the relationship between complex traits 
Specific Aim II:  To explore the relationship between serum 2OHE1:16OHE1 EMR and 
mammographic density, in a cohort of healthy, pre- and postmenopausal African American and 
Caucasian women. 
Given the classical method of endocrinology and the use of postmenopausal women, the 
estrogen metabolites found in the blood will provide the best assessment of the estrogens being 
produced, as the ovaries in these women no longer produce sufficient quantities of estrogen.  
This investigation will provide insight to the disparity among African American women by 
revealing whether or not race influences the 2OHE1:16OHE1 EMR.  We will also evaluate the 
relationship between this ratio and mammographic density, as well as other known breast cancer 
risk factors.  We hypothesize a negative association will be observed with mammographic 
density and the 2OHE1:16OHE1 EMR, as increased breast density is associated with increased 
breast cancer risk.  We also hypothesize that a negative relationship will be observed when 
evaluating the association between race and the 2OHE1:16OHE1 EMR.  The risk of developing 
breast cancer for African American women is greatest under the age of 40, after this age, the risk 
becomes greater for Caucasian women, yet the mortality rate of African American women 
exceeds that of Caucasian women at every age.  Therefore, we expect there to be a negative 
relationship between race/ethnicity and the 2OHE1:16OHE1 EMR.  
An In Vitro Analysis of the 2OHE1:16OHE1 Estrogen Metabolite Ratio in Breast Epithelial Cells 
Specific Aim III:  To determine the 2OHE1:16OHE1 EMR in normal and tumor breast epithelial 
cell lines of African American and Caucasian women. 
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Evidence now suggests that the estrogens produced locally are capable of exerting a 
maximum effect, with only modest quantities.  This novel in vitro assay will assess the 
2OHE1:16OHE1 EMR in normal and tumor established breast epithelial cell lines derived from 
African American and Caucasian women.  This evaluation has great implications, as to date; no 
other study has compared the effects of estradiol treatment in cell lines derived from these two 
racial/ethnic groups.  We hypothesize that there will be a significant difference in the mean 
2OHE1:16OHE1 EMR in tumor versus normal cells, in cell lines derived from African American 
versus Caucasian women, and in treated versus untreated cell lines.  We also hypothesize that 
cell type, race, and estradiol treatment will all be significant predictors of the 2OHE1:16OHE1 
EMR. 
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3.1 ABSTRACT 
Purpose:  Urinary levels of the ratio of two estrogen metabolites, 2 – hydroxyestrone (2OHE1) 
and 16α – hydroxyestrone (16OHE1) have been implicated as a marker of breast cancer risk.  The 
Leu432Val polymorphism in the estrogen metabolism gene, Cytochrome P450 1B1 (CYP1B1), 
has been found to be associated with urinary levels of the 2OHE1:16OHE1 estrogen metabolite 
ratio (EMR).  The objective of this study was to determine if the Leu432Val polymorphism has 
any influence on breast cancer risk through variations in the urinary 2OHE1:16OHE1 EMR.  
Methods:  A case-control population of 137 Caucasian women was analyzed.  Cases were 
identified through the Breast Cancer Surgical Registry at Magee-Women‟s Hospital, Pittsburgh, 
PA, while controls were obtained from previous genetic association studies.  Urinary estrogen 
metabolites were assayed using a basic Enzyme Linked Immunosorbent Assay (ELISA), and 
genotyping was done using a basic Restriction Fragment Length Polymorphism-PCR.  Results:  
A significant association between the 2OHE1:16OHE1 EMR and breast cancer was observed (OR 
= 0.289; 95% CI 0.137 – 0.613; p = 0.0012).  Overall, the CYP1B1 Leu432Val polymorphism 
was not associated with breast cancer risk, but was associated with the 2OHE1:16OHE1 EMR (p 
<0.0001).  Associations with other known risk factors, such as age (p = 0.0064) and an age and 
BMI interaction (p = 0.0397), were also found.  Conclusion:  The urinary 2OHE1:16OHE1 EMR 
may play a role in modifying breast cancer risk.  The CYP1B1 genotype does not appear to 
mediate this risk, but if it has any role in breast cancer risk, it may do so through variations in the 
2OHE1:16OHE1 EMR. 
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3.2 INTRODUCTION 
Since the report that estrogens are associated with breast cancer, epidemiological studies have 
focused on the effects that estrogen metabolites may have in modifying breast cancer risk (T. H. 
Lippert et al., 2000).  The ratio of two metabolites, 2-hydroxyestrone (2OHE1) and 16α-
hydroxyestrone (16OHE1), has been implicated as a marker of breast cancer risk due to their 
contrasting biological properties (Lord et al., 2002).  2OHE1 is capable of binding to the estrogen 
receptor (ER) with markedly reduced binding affinity, thus showing weakly estrogenic 
properties.  Conversely, 16OHE1 is a potent estrogenic molecule that functions by activating the 
ER (Zhu & Conney, 1998).  Therefore, the ratio of 2OHE1 and 16OHE1 appears to regulate the 
proportion of anti-estrogenic molecules to estrogenic ones.  It is hypothesized that women who 
metabolize estrogen primarily through the 2OHE1 pathway have a lower risk of developing 
breast cancer, while those who metabolize estrogens principally through the 16OHE1 pathway, 
are at an increased risk of developing breast cancer (C. Lippert, Seeger, & Mueck, 2003). 
Estrogen biosynthesis and metabolism is catalyzed by the Cytochrome P450 (CYP) 
superfamily of genes, which encode a number of enzymes that are directly involved in drug and 
steroid metabolism (Nebert & Russell, 2002).  The CYP1B1 gene maps to chromosome 2p22-
p21, and consist of three exons and two introns, which contain the entire coding sequence of the 
gene (Paracchini et al., 2005; Paracchini et al., 2007).  An inducible enzyme capable of initiating 
a variety of carcinogens such as arlyamines, nitrosamines, and arylenes, CYP1B1 is expressed in 
a number of tissues including the kidney, prostate, uterus, ovary, and breast (Beuten et al., 2008; 
Ingelman-Sundberg, 2004; Paracchini et al., 2005).  In the breast, this gene is believed to be 
involved in the metabolic regulation of estrogen homeostasis, and is highly expressed in breast 
tumors (Ingelman-Sundberg, 2004; Paracchini et al., 2005).  Evidence also suggests that CYP1B1 
40 
is responsible for the hydroxylation of estradiol at the C-16 position, leading to the formation of 
16OHE1 (Badawi et al., 2001; Cribb et al., 2006; Lord et al., 2002; Tsuchiya et al., 2005).  This 
implies that variation in this gene could modify estradiol catabolism, and may in turn alter breast 
cancer risk. 
A single nucleotide polymorphism (SNP) located at position 1666 in exon 3, is a C→G 
transversion, which results in an amino acid substitution of leucine (Leu) to valine (Val) at codon 
432 (Paracchini et al., 2005).  Exon 3 codes for the heme-binding domain of the gene, a region 
that is critical to its catalytic function.  While the mechanistic function of this SNP is unknown, it 
is believed to affect mRNA stability, and may be in linkage disequilibrium with transcriptional 
regulatory sequences such as response elements, or the regulating elements of RNA degradation 
of other CYP1B1 variants (Paracchini et al., 2007).  Previous literature suggests that the presence 
of the variant valine allele is associated with increasing breast cancer risk, yet these results are 
inconsistent (Greendale et al., 2005; Le Marchand, Donlon, Kolonel, Henderson, & Wilkens, 
2005; Long et al., 2007; Rylander-Rudqvist et al., 2003; Sowers, Wilson, Karvonen-Gutierrez, & 
Kardia, 2006). 
In a meta and pooled analysis by Paracchini, Raimondi, Gram, et al. (2007), the authors 
observed racial, as well as age differences in the association between the CYP1B1 Leu432Val 
polymorphism and breast cancer risk.  A possible association between the CYP1B1 Leu432Val 
polymorphism and breast cancer was found, but only among Caucasians.  Furthermore, this 
effect was not seen among Asians, and a possible negative association was found among African 
American or mixed populations.  Additionally, among Caucasians, the results of their pooled 
analysis revealed a significant age effect, with an increase risk of breast cancer occurring 
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between the ages of 45 and 59 years, while this risk was much lower for both younger and older 
women (Paracchini et al., 2007). 
The purpose of this study was to evaluate the effects of the CYP1B1 genotype on the 
urinary 2OHE1:16OHE1 EMR and the association of the CYP1B1 genotype and 2OHE1:16OHE1 
EMR on breast cancer.  The role of other known breast cancer risk factors, including age, BMI, 
and smoking status was also assessed. 
3.3 MATERIALS AND METHODS 
3.3.1 Study Population 
A total of 137 Caucasian women were selected for this study.  Participants‟ ages ranged from 20 
to 78 years.  Thirty-three cases were identified through the Breast Cancer Surgical Registry at 
Magee Women‟s Hospital, Pittsburgh, PA.  This database, developed in 2005, consists of women 
undergoing breast cancer surgery at Magee Women‟s Hospital that consented to being added the 
registry (Im et al., 2009).  A urine sample and matching breast epithelial tissue sample were 
obtained for each case.  A total of 104 control participants were recruited to take part in several 
studies, and are described elsewhere (Paracchini et al., 2005).  These investigations include 
analyses on the genetics of bone density, a study regarding diet and genetic factors, and a study 
on the effects of indole-3-carbinol on urinary estrogen metabolites.  All control participants 
provided a urine sample and matching peripheral blood sample for genetic analysis. 
Demographic variables such as age, BMI, and smoking status, were collected utilizing 
questionnaire data from controls, and the medical records of cases. BMI was calculated by 
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dividing the participants‟ weight in kilograms by their height in meters squared, while smoking 
status was a dichotomous variable, classifying subjects as “never” or “ever” smokers.  Age and 
the 2OHE1:16OHE1 EMR are continuous variables, while the CYP1B1 genotypes were 
categorized according to the subjects‟ respective genotype (i.e. reference genotype – Leu/Leu; 
heterozygous genotype – Leu/Val; homozygous variant – Val/Val).  
3.3.2 DNA Extraction and Genotyping 
Genomic DNA was extracted from the breast epithelial tissue and peripheral blood samples 
using the DNA extraction kit developed by Stratagene (Stratagene, LaJolla, CA) and Gentra-
System Tissue Kit (QIAGEN, Minneapolis, MN), respectively, according the manufacturer‟s 
instructions.  The CYP1B1 genotype was determined using RFLP PCR in 50µl reactions 
(forward and reverse primers: 5‟-CTGCCAACACCTCTGTCTTG-3‟ and 5;-
CTGAAATCGCACTGGTGAGC-3‟).  PCR was performed at 95º C for 10 minutes, and 35 
cycles at 95ºC, 60 ºC, and 72ºC for 1 minute each.  A final annealing cycle was conducted at 72ºC 
for 7 minutes and 12ºC for 9 hours.  The PCR products were then digested utilizing Eco571 
restriction digest in a 30µl reaction at 37 ºC for 12 hours.  Digestion products were verified on a 
2% agarose gel. 
3.3.3 2OHE1:16OHE1 Estrogen Metabolite Assay 
To quantify urinary concentrations of 2OHE1 and 16OHE1, an Enzyme Linked Immunosorbent 
Assay (ELISA) purchased from the Immuna Care Corporation (Immuna Care, Bethlehem, PA) 
was used.  The estrogens were deconjugated by the addition of a β-glucuronidase and an 
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arlysulphatase enzyme.  Seventy-five microliters of the enzyme digest were added to two (2) 96 
well microtiter plates, one labeled “2OHE1” and the other “16OHE1.”  These plates were then 
coated with anti-2OHE1 and anti-16OHE1 monoclonal antibodies.  An alkaline phosphatase 
solution containing monoclonal antibodies to 2OHE1 and 16OHE1 was added directly to each 
well.  After incubation, a basic solution of paranitrophenyl phosphate (pNPP) was added to 
detect the alkaline phosphate solution (Klug, Bradlow, & Sepkovic, 1994).  The microtiter plates 
were read using a Biotek ELx808 plate reader at 405 nm. 
3.3.4 Statistical Analysis 
All analyses were conducted using SAS version 9.2 (SAS Institute, Cary, North Carolina) 
software, and a 2-sided alpha level of 0.05.  Logistic regression analysis was conducted to 
estimate odds ratios (OR) and 95% confidence intervals (CI) for the association between case-
control status and the 2OHE1:16OHE1 EMR, the CYP1B1 genotype, age, BMI, and smoking.  
Potential interactions, such as genotype and the 2OHE1:16OHE1 EMR; BMI and 
2OHE1:16OHE1 EMR; age and BMI; age and 2OHE1:16OHE1 EMR; and the 2OHE1:16OHE1 
EMR and smoking status were also examined. 
Linear regression analyses of the 2OHE1:16OHE1 EMR on CYP1B1 genotype, BMI, age, 
and case-control status were conducted to evaluate the association between the CYP1B1 
Leu432Val polymorphism and the 2OHE1:16OHE1 EMR separately in cases and controls.  
Potential interactions between age, BMI, and smoking were also investigated.  For all regression 
analyses, the CYP1B1 genotype was identified as 0 (reference genotype), 1 (heterozygous), 2 
(homozygous variant). 
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3.4 RESULTS 
Values for the 2OHE1:16OHE1 EMR ranged from 0.165611 to 5.20098, however one subject had 
a value of 19.30287, which was considered an extreme outlier.  As a result, this observation was 
removed from all analyses to avoid extreme influential effects.  Therefore, only 136 participants 
(104 controls and 32 cases) were included in the analysis.   
Table 4 contains a detailed description of the study population.  We observed that cases 
and controls differed significantly in age and BMI, (p < 0.0001) and (p < 0.0001), respectively.  
Additionally, a significantly lower 2OHE1:16OHE1 EMR was found among cases when 
compared to controls (1.42 versus. 2.11; p < 0.0003).  Similarly, there was also a statistical 
difference in the CYP1B1 genotype frequency between cases and controls (Armitage trend test p 
= 0.0129).  As there were so few smoking breast cancer cases in comparison to controls, this 
variable was removed from further analyses. 
Table 4.  Breast Cancer Case-Control Study Population Characteristics 
 Cases Controls p – value 
 N = 32 N = 104  
Age, years. (ȳ) 56.0 35.1 <0.0001 
BMI (ȳ) 27.8 22.8 <0.0001 
2OHE1:16OHE1 EMR (ȳ) 1.42 2.11 0.0003 
CYP1B1 Genotype* 
Leu/Leu: 12 Leu/Leu: 18 
0.0129** Leu/Val: 16 Leu/Val: 59 
Val/Val: 4 Val/Val: 27 
Smoking Status 
Never: 29 Never: 80 
0.0147*** 
Ever: 3 Ever: 24 
*Hardy Weinberg Equilibrium χ2 = 0.2297, ** Armitage trend test, ***Fisher‟s exact p- value 
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Logistic regression modeling was used to identify key variables that significantly predict 
the likelihood of being a case or a control (Table 5).  The only statistically significant variables 
that contributed to the prediction of case status were age and the 2OHE1:16OHE1 EMR (p < 
0.0001 and p < 0.0012, respectively).  In fact, there was a positive relationship with age that 
increased the odds of being a case by 16% (OR = 1.161; 95% CI 1.094 – 1.233).  On the other 
hand, a negative relationship was observed between the 2OHE1:16OHE1 EMR and case status, 
which decreased the risk of being a case by approximately 71% (OR = 0.289; 95% CI 0.137 – 
0.613).  However, the CYP1B1 genotype was not a predictor of breast cancer status.  Interactions 
between the 2OHE1:16OHE1 EMR and CYP1B1 genotype; BMI and the 2OHE1:16OHE1 EMR; 
age and the 2OHE1:16OHE1 EMR; and age and BMI were also evaluated, yet, no significant 
relationships were observed. 
Table 5.  Predictors of Breast Cancer 
Variable 
Parameter 
Estimate 
OR 95% CI p value 
Age* 0.1497 1.161 (1.094 - 1.233) <0.0001 
2OHE1:16OHE1 
EMR* 
-1.2399 0.289 (0.137 – 0.613) 0.0012 
CYP1B1* -0.3725 0.689 (0.271 – 1.755) 0.4348 
BMI* 0.0693 1.048 (0.915 – 1.200) 0.5007 
EMR*CYP1B1€ -0.1910   0.7570 
BMI*2OHE1:16OHE1 
EMR€ 
-0.0412   0.6437 
Age*2OHE1:16OHE1 
EMR€ 
0.0223   0.3425 
Age*BMI€ -0.00625   0.1450 
* Logistic Regression model 1; € Logistic Regression model 2 
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Multiple linear regression analyses were conducted to evaluate the association between 
the 2OHE1:16OHE1 EMR and the CYP1B1 genotype (Table 6).  Among all participants, 
significant positive associations between age, the CYP1B1 genotype, and the 2OHE1:16OHE1 
EMR were observed (age: p = 0.0014; CYP1B1: p = 0.0294).  A significant inverse association 
between case-control status and the 2OHE1:16OHE1 EMR was also observed (p<0.0001).  Since 
age and BMI are two highly correlated variables, the interaction between these two and the 
2OHE1 16OHE1 EMR: was assessed, however, this did not reach statistical significance. 
Table 6.  Association between the 2OHE1:16OHE1 EMR and the CYP1B1 genotype 
Variable Parameter Estimate p - value 
Age 0.08432 0.0014 
CYP1B1 Genotype 0.28558 0.0294 
BMI 0.02391 0.6555 
Case/Control Status -1.1317 <0.0001 
Age*BMI -0.00168 0.1001 
 
To determine if the prediction of the 2OHE1:16OHE1 EMR varied by case-control status, 
additional linear regression analyses stratified by case-control status were conducted (Table 7).  
Among cases, age was positively associated with the 2OHE1:16OHE1 EMR, while the age and 
BMI interaction was negatively associated with the 2OHE1:16OHE1 EMR (age: p = 0.0064; 
age*BMI: p = 0.0397). The control population also exhibited a positive relationship between 
2OHE1:16OHE1 EMR and age, as well as a positive relationship with the CYP1B1 genotype 
(age: p = 0.0081; CYP1B1: p = 0.0249).  The interaction between age and BMI was not 
statistically significant (p = 0.0599) (Table 7b). 
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Table 7.  Association between the 2OHE1:16OHE1 EMR and the CYP1B1 genotype 
Stratified by Case-Control Status 
Cases Only 
Variable Parameter Estimate p - value 
Age 0.18125 0.0064 
CYP1B1 Genotype 0.26883 0.2815 
BMI 0.21430 0.1114 
Age * BMI -0.00462 0.0397 
Controls Only 
Variable Parameter Estimate p - value 
Age 0.13208 0.0081 
CYP1B1 Genotype 0.34863 0.0249 
BMI 0.08449 0.2884 
Age * BMI -0.00380 0.0599 
 
3.5 DISCUSSION 
The results of this study demonstrate an association between the 2OHE1:16OHE1 EMR and 
breast cancer.  Additionally, the analysis suggests that having a high 2OHE1:16OHE1 EMR is 
associated with a lower probability of developing breast cancer, and vice versa.  These findings 
are in line with several studies.  A small case-control study reported that postmenopausal women 
who developed breast cancer at least 6-months after baseline, had 2OHE1:16OHE1 EMR levels 
approximately 15% lower than matched controls.  The authors also observed that participants 
with 2OHE1:16OHE1 EMR levels in the highest tertile experienced an approximately 30% lower 
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risk of developing breast cancer, than those in the lowest tertile (OR = 0.71; 95% CI 0.29 – 1.75; 
p = 0.46); however, the study lacked sufficient power to detect this difference (Meilahn et al., 
1998).  Nonetheless, similar results were observed in another case-control study, in which 
postmenopausal cases had significantly lower 2OHE1:16OHE1 EMR than did controls (cases: 
1.41 ± 0.73 vs. controls: 1.81 ± 0.71; p – value = 0.05) (Kabat, Chang, & Sparano, 1997).  An 
additional study reported that greater hydroxylation at the C-2 position was associated with a 
reduction in invasive breast cancer risk among premenopausal women, and those whose with a 
2OHE1:16OHE1 EMR in the highest quintile reduced their risk of invasive breast cancer 
approximately 20% compared to the relative risk of those in the lowest quintile (lowest quintile 
[≤ 1.80] = 0.76; highest quintile [≥ 3.29] = 0.55) (Muti et al., 2000).  These results were also 
duplicated in another study by Kabat et al. in 2006, but only in premenopausal women (Kabat et 
al., 2006). 
Conversely, an analysis investigating urinary levels of the 2OHE1:16OHE1 EMR in a 
population of only postmenopausal women, did not observe any evidence to suggest that a high 
2OHE1:16OHE1 EMR was associated with a decrease in breast cancer risk (mid-tertile [1.17 – 
1.73] OR = 0.34; 95% CI 0.12 – 0.98; highest tertile [>1.73] OR = 1.13; 95% CI 0.46-2.78; p for 
trend = 0.96).  This result remained constant even after adjustment for dietary intake (mid-tertile 
[1.17 – 1.73] OR = 0.32; highest tertile [>1.73] OR = 1.14) (Ursin et al., 1999).  Likewise, a 
prospective study reported that increased concentrations of 2OHE1 were associated with an 
increased risk of estrogen-receptor positive breast cancer, among postmenopausal, current HRT 
users, while 16OHE1 levels were not found to be significantly associated with breast cancer 
(Wellejus et al., 2005).  Another study assessed urinary levels of the 2OHE1:16OHE1 EMR 
before and after breast cancer treatment, and found that the association between the 
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2OHE1:16OHE1 EMR and breast cancer is modified by the urine collection protocol.  The 
authors noted that in samples taken prior to surgery or other forms of breast cancer treatment, 
that an increased 2OHE1:16OHE1 EMR was associated with lower breast cancer risk, while in 
post surgical/post-treatment samples, an increased 2OHE1:16OHE1 EMR was associated with 
increased breast cancer risk (Fowke et al., 2003). 
While no significant relationships between the CYP1B1 genotype and breast cancer were 
found, we did observe a significant association between the CYP1B1 genotype and the 
2OHE1:16OHE1 EMR.  From this finding, one can imply that if this genotype modifies breast 
cancer risk, it may do so by altering the 2OHE1:16OHE1 EMR.  Paracchini et al (2005) studied 
the link between the 2OHE1:16OHE1 EMR and the CYP1B1 Leu432Val polymorphism.  This 
analysis consisted of 150 healthy men and premenopausal women.  The healthy women present 
in our analysis were a subset of the women published by Paracchini et al.  The authors observed 
that the presence of the valine allele was associated with an increased urinary 2OHE1:16OHE1 
EMR among Caucasian women (CYP1B1 Val/Val = 1.95 ±. 1.06; CYP1B1 Val/Leu = 2.08 ± 
1.06; CYP1B1 Leu/Leu = 2.55 ± 1.37) (Paracchini et al., 2005).  Our data is consistent with this 
finding with respect to controls. 
When evaluating the relationship between other known risk factors for breast cancer and 
the 2OHE1:16OHE1 EMR, we observed a significant, positive association between age and the 
2OHE1:16OHE1 EMR.  To date, we have identified only one study that has examined the 
association between the 2OHE1:16OHE1 EMR and age, and no significant relationship was 
found (Kabat et al., 1997).  Obesity has long been a known risk factor for breast cancer, 
especially among postmenopausal women; given that the large majority of estrogens are 
produced by adipose tissue (Baglietto et al., 2008; Clemons & Goss, 2001; Dignam et al., 2006).  
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Furthermore, overweight, postmenopausal women have been reported to be at an increased risk 
of developing estrogen-positive tumors (Palmer, Adams-Campbell, Boggs, Wise, & Rosenberg, 
2007).  In the present study, we were able to demonstrate a significant, inverse relationship 
between the 2OHE1:16OHE1 EMR and the age*BMI interaction, two known risk factors for 
breast cancer risk that are highly correlated.  In a case-control study by Modugno et al (2006), 
the authors found that among women not using hormone therapy, low serum levels of 2OHE1 in 
combination with a high BMI, increased ones risk of developing breast cancer (adjusted OR = 
3.67; 95% CI 1.26 – 10.95), while those with high concentrations of serum 16OHE1 and a high 
BMI were also at an increased risk of developing breast cancer (adjusted OR = 3.51; 95% CI 
1.34 – 9.16) (Modugno, Kip et al., 2006).  While very few studies assess the relationship 
between other breast cancer risk factors and the 2OHE1:16OHE1 EMR, an early study evaluated 
the association between this ratio and having a family history of breast cancer in a population of 
premenopausal women; however, no difference was detected between the two groups (Ursin et 
al., 2002). 
Breast cancer is a complex disease, with both genetic and environmental factors 
mediating ones risk of developing this disease.  The objective of this study was to evaluate 
whether or not the Leu432Val polymorphism in the estrogen metabolism gene, CYP1B1, has any 
influence on the urinary 2OHE1:16OHE1 EMR, which has been implicated as a marker of breast 
cancer risk.  Given the potential of this gene variant to alter estrogen metabolism, this SNP has 
been extensively studied to determine its association with breast cancer and other known risk 
factors for breast cancer as well (Han et al., 2004; Hanna, Dawling, Roodi, Guengerich, & Parl, 
2000; Rylander-Rudqvist et al., 2003; Van Emburgh et al., 2008).  While we did not observe a 
direct association with the CYP1B1 genotype and breast cancer, previous studies have supported 
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the presence of a relationship.  A case-control study conducted in Turkey (Kocabas et al. (2002)) 
assessed the association of the CYP1B1 Leu432Val polymorphism and breast cancer.  The 
authors found that the presence of the valine allele was associated with a significantly increased 
susceptibility to breast cancer.  The adjusted odds ratio for age, age at menopause, age at first full 
term pregnancy, BMI, and smoking status was 2.32 (95% CI 1.26 - 4.25; p = 0.007).  The 
authors also observed that the CYP1B1 genotype was related to breast cancer among women with 
a BMI greater than 24 kg/m2 (adjusted OR =  2.78; 95% CI 1.36 - 5.62; p = 0.005) (Kocabas et 
al., 2002). 
Although our study presents the findings of some novel research, it is also subject to 
several limitations.  A case-control study is a useful first step when exploring a source of disease, 
and allowed us to investigate a variety of characteristics that may lead to an adverse health 
outcome, we were unable to obtain the absolute risk (incidence) of disease, nor could we 
determine the relative risk of disease in the study population (Gordis, 2004).  Furthermore, the 
use of a study population that consisted only of Caucasian women prevented applicable 
comparisons to other racial/ethnic groups.  We also observed some dissimilarities between our 
cases and controls (e.g., age and BMI) that make drawing solid conclusions difficult. 
Selection bias may also have been introduced into our research, as our controls were 
obtained from other studies.  Therefore, the selection, as well as exclusion criteria may have 
differed for each group.  Other limitations include reporting and recall bias, due to the use of 
self-reported questionnaires, and small sample sizes, which limited our power of detection. 
Another limitation of this study was the inability to more accurately assess the role of the 
CYP1B1 Leu432Val polymorphism in breast cancer risk.  We have, however, shown an 
association between this polymorphism and the 2OHE1:16OHE1 EMR and a relationship 
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between 2OHE1:16OHE1 EMR and breast cancer risk.  Additionally, the large majority of 
examinations assessing the 2OHE1:16OHE1 EMR and breast cancer risk, are case – control 
studies, that do not investigate the contributing factors to the 2OHE1:16OHE1 EMR.  For this 
reason alone, our research is a great contribution to the literature.   
In conclusion, our data suggests that the 2OHE1:16OHE1 EMR is associated with breast 
cancer risk.  While we were unable to detect a direct association between the CYP1B1 
Leu432Val polymorphism and breast cancer risk, we have demonstrated that the CYP1B1 
genotype is associated with the 2OHE1:16OHE1 EMR, thereby suggesting that the CYP1B1 
Leu432Val polymorphism may alter breast cancer risk by modifying this ratio. 
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4.1 ABSTRACT 
Purpose:  Mammographic density is one of the strongest predictors of breast cancer risk.  
While the role of estrogens in breast cancer risk has long been established, the association 
between estrogen metabolites and mammographic density has not been fully elucidated.   This 
study assesses the relationship between mammographic density and serum concentrations of the 
2OHE1:16OHE1 EMR according to race.  Methods:  The study population consisted of 120, 
cancer-free participants from the Mammograms and Masses Study.  Serum estrogen metabolites 
were assayed by the Immuna Care Corp, utilizing a competitive, solid-phase enzyme 
immunoassay.  Mammographic density was measured using the classification by Wolfe and a 
compensating polar planimeter.  Results:  Percent mammographic density was significantly 
lower in black than in white women, but no significant associations with the 2OHE1:16OHE1 
EMR were observed.  BMI and smoking were significantly inversely associated with percent 
mammographic density in white women, while no significant predictors of percent 
mammographic density were found among black women.  Conclusion:  Serum concentrations of 
the 2OHE1:16OHE1 EMR are not associated with percent mammographic density.  Predictors of 
mammographic density are different between black and white women, suggesting different 
biological pathways to breast carcinogenesis.   
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4.2 INTRODUCTION 
One of the strongest predictors of breast cancer risk is mammographic density (Baglietto et al., 
2008; Bremnes, Ursin, Bjurstam, Rinaldi et al., 2007; Crandall et al., 2008; Greendale et al., 
2005; Gruber et al., 2002; Johansson et al., 2008; Tamimi et al., 2007; Tamimi et al., 2005).  In 
fact, the risk of developing breast cancer associated with mammographic density is greater than 
the d risk of pall other clinical risk factors (Greendale et al., 2005).  Mammographic density is 
the proportion of fibrous, connective and epithelial tissue, to total breast area (Aiello et al., 2005; 
Martin & Boyd, 2008; Vachon et al., 2000).  Women with mammographic breast density greater 
than or equal to 75%, are at a four to six-fold greater risk of developing breast cancer when 
compared to those with no measurable dense tissue (Aiello et al., 2005; N. F. Boyd et al., 2009; 
Greendale et al., 2005; Tamimi et al., 2007; Tamimi et al., 2005). 
While the biological mechanism through which mammographic density predicts breast 
cancer risk is unknown, many of the established risk factors for breast cancer have also been 
shown to be associated with variations in breast density (i.e., age, menopausal status, parity, 
BMI, and HRT) (N. F. Boyd et al., 2009; Haiman et al., 2003; Vachon et al., 2000; Warren et al., 
2006; Woolcott et al., 2009).  As these risk factors all share a relationship to circulating hormone 
levels, investigators have sought to determine the role of endogenous estrogens on 
mammographic density.  It has been hypothesized that breast density is related to cumulative 
estrogen exposure, and that more dense breasts represents increased cellular proliferation (Ziv et 
al., 2004).  However, few studies have examined the association between estrogen metabolites 
and mammographic density. 
The ratio of two particular estrogen metabolites, 2-hydroxyestrone (2OHE1) and 16α-
hydroxyestrone (16OHE1), has long been implicated as a marker of breast cancer risk.  2OHE1 is 
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believed to be devoid of estrogenic property, while 16OHE1 is believed to be an estrogenic 
compound, and as such has been shown to significantly increase cell proliferation.  Therefore, it 
is hypothesized that women who metabolize estrogen primarily through the 2OHE1 pathway 
have a lower risk of developing breast cancer, and vice versa for the 16OHE1 pathway (Seeger et 
al., 2006; Vandewalle & Lefebvre, 1989; Zhu & Conney, 1998). 
In this study, the association between mammographic density and the 2OHE1:16OHE1 
EMR has been assessed in a population of healthy black and white women.  Breast cancer is the 
most commonly diagnosed cancer among black women in the US.  From 2001 to 2005, African 
American women experienced a 37% higher mortality rate than Caucasian women (American 
Cancer Society, 2008a, 2009).  Furthermore, women of African descent are more likely to be 
diagnosed with breast cancer at a more advanced stage (which includes some stage III and stage 
IV tumors); are more likely to have larger, estrogen-negative, high grade tumors; and are more 
likely to have lymph node involvement, all of which are poor prognostic predictors of survival 
(Breastcancer.org, 2008; Chlebowski et al., 2005; Curtis et al., 2008).  Current studies evaluating 
mammographic breast density in black women have been inconsistent.  Some have reported that 
these women have significantly greater breast density than do white women (Chen et al., 2004; 
El-Bastawissi et al., 2001), but others  have  reported that black women have lower breast 
density when compared to white women (del Carmen et al., 2003; Ursin et al., 2003), or no 
difference in mammographic breast density, when comparing these two racial/ethnic groups (del 
Carmen et al., 2007).  The present study explores the association between estrogen metabolites 
and breast density, while highlighting any potential differences that may occur by race. 
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4.3 MATERIALS AND METHODS 
4.3.1 Study Population 
This study population consisted of 120 participants from the Mammograms and Masses Study 
(MAMS), which is composed of pre- and postmenopausal women, age 18 and older, showing no 
sign of breast cancer after mammography or biopsy.  Participants were excluded if they had a 
prior history of cancer (excluding cancer of the skin), drank more than five drinks per day, or 
weighed less than 110 pounds or greater than 300 pounds.  Participants were enrolled from 
September 2001 until May 2005 from three hospital sources: 1) the Diagnostic Imaging Clinic at 
Magee-Women‟s Hospital, Pittsburgh, PA, 2) the Surgical Clinic at Magee-Women‟s Hospital, 
and 3) Magee-Women‟s Hospital or Magee Woman-care mammography clinics in the Pittsburgh 
area.  Women receiving routine mammography screening exams were identified as „well 
controls,‟ and were recruited through a study flyer that was attached to their negative screening 
results.  Other participants with a suspicious lesion that was identified during mammography, 
and subsequently underwent breast biopsy were personally recruited by the research assistant 
during their visit to the Breast Biopsy Service if their biopsy showed no sign of cancer.  The 
original MAMS study includes a total population of 1, 133 participants, in which personal 
medical history, HRT use, family history, and other demographics were obtained via self-report 
questionnaires, and non-fasting blood samples were taken. A subset of the population, 424 
women (~30%) had serum estrogen metabolite measured.   
This subpopulation included 374 Caucasians, 40 African Americans, and 10 participants 
that identified themselves as Asian/Pacific Islander, Hispanic/Latina, American Indian, or 
“other.”  For the present study, all African American samples (40) matched on age and 
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menopausal status to 80 Caucasian women (N= 120) were selected.  This study was approved by 
the Institutional Review Board of the University of Pittsburgh (Reeves, Gierach, & Modugno, 
2007). 
4.3.2 Measures of Mammographic Density 
Consent was obtained from all MAMS participants for the research staff to receive copies of 
the participant‟s original screening mammogram that were taken immediately before the 
participant‟s breast biopsy or the corresponding mammogram to which the recruitment flyer was 
attached.  Three different measures of mammographic density (dense breast area, total breast 
area, and percent breast density) were analyzed by M.S., an expert reader (Benichou et al., 2003; 
Haiman et al., 2003; Wolfe, Saftlas, & Salane, 1987).  For all measures, the craniocaudal view 
was used, unless unavailable, wherein the mediolateral view was used instead.  The reader was 
blinded to the identity of all mammograms.  Participant‟s mammograms were analyzed with two 
different methods.  The first approach involved visual inspection, and classification based on the 
system developed by Wolfe in 1976 (Wolfe, 1976).  Each participant was placed into one of the 
four parenchymal pattern categories: N1 = little to no measurable dense tissue, where the risk of 
breast cancer is lowest; DY = mammographically dense breast, where the risk of breast cancer is 
highest; P1 and P2 = variable density levels, where the risk of breast cancer intermediate (Boyd 
et al., 2005).  The second method involved a compensating polar planimeter (LASICO, Los 
Angeles, CA), a wax pencil, and a transparent overlay, to outline the entire breast, and areas of 
dense tissue, to quantify total breast area, and dense breast area.  Breast density was calculated as 
the proportion of visibly dense breast to total breast area, expressed as a percentage. 
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To evaluate the reproducibility of the readings, a random sample of 28 mammograms 
were reassessed, and intraclass correlation coefficients (ICC) for intra-observer agreement were 
calculated for measure of breast density.  The ICC for dense area measurements was ρ=0.86, 
ρ=0.99 for total area, and ρ=0.89 for percent breast density, indicating high reproducibility.  The 
ICC derived for percent density is consistent with the reproducibility by the same reader in the  
Breast Cancer Detection Demonstration Project (Benichou et al., 2003). 
4.3.3 ESTRAMETTM 2OHE1 and 16OHE1 Serum Assay 
All serum estrogen metabolites were assayed using the ESTRAMETTM 2OHE1 and 
16αOHE1 Serum Assay, in the laboratory of Dr. Thomas Klug (Immuna Care, Bethlehem, PA).  
This assay is a competitive, solid-phase enzyme immunoassay.  First, each antigen, 2OHE1 or 
16OHE1 was conjugated to an alkaline phosphatase solution.  This enzyme-conjugate solution 
was then added to the specified 96-well microtiter plate, coated with anti-2OHE1 or anti-16OHE1 
monoclonal antibodies, and incubated overnight.  The microtiter plates were then washed, and a 
colored enzyme substrate solution was added, eliciting a chemical reaction with the antigen-
enzyme conjugate bound to the plate.  The plates were then read by a microtiter plate reader at 
620 nm.  This assay has a sensitivity of less than 20pg/ml for both 2OHE1 and 16OHE1.  The 
coefficient of variation (CV) for 2OHE1 ranged from 0.0 – 14.4, with only three samples having 
CVs outside of this range.  CV values for 16OHE1 ranged from 1.3 to 17.9, with only one 
observation having a value outside of this range. 
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4.3.4 Statistical Analysis 
All analyses were conducted using SAS version 9.2 (SAS Institute, Cary, North Carolina) 
software, and a 2-sided alpha level of 0.05.  Two sample t-tests were utilized to assess mean 
differences between continuous variables, and χ2 tests were used to analyze discrete measures.  
Linear regression modeling was utilized to evaluate the relationship between mammographic 
density and the 2OHE1:16OE1 EMR.  Demographic variables, such as age, BMI, race, family 
history of breast cancer, pregnancy status, number of live births, OC use, smoking status, HRT, 
and menopausal status, were included in all models, based on the results of previous literature 
that indicate the significant impact these factors have on mammographic density (N. F. Boyd et 
al., 2009; Haiman et al., 2003; Vachon et al., 2000; Warren, 2004; Woolcott et al., 2009).  Age 
and BMI were added to the models as continuous variables, while the remaining variables (race, 
family history of breast cancer, pregnancy status, number of live births, OC use, smoking status, 
HRT, and menopausal status) were identified as categorical variables, and dummy variables were 
created as necessary.  Subsequent analyses were also stratified by race, to evaluate if the 
relationship between mammographic density and the 2OHE1:16OE1 EMR varied by race. 
An initial review of the data showed that the 2OHE1:16OHE1 EMR and the percent 
density variable were not normally distributed; therefore, the 2OHE1:16OHE1 EMR ratio were 
log transformed, and percent density was square root transformed, in order to normalize the data.  
However, the results are presented in the untransformed version for easy interpretation.  
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4.4 RESULTS 
Of the total population, 42 participants were diagnosed with benign breast disease (BBD) 
Preliminary analyses were conducted to assess the relationship between BBD and 
mammographic density, but these results did not reveal any statistically significant difference in 
percent density between „well controls‟ and those diagnosed with BBD.  Similar results were 
obtained when stratified these analyses by race (data not shown).  Therefore, all study 
participants were analyzed together. 
The participants had a mean age of 55 years, were mostly postmenopausal, overweight, 
non-smoking women.  Additionally, the majority of women did not have a family history of 
breast cancer and had given birth three or more times.  Overall, the mean percent density of our 
study population was 30.9% (Table 1). 
Table 8.  MAMS Study Population Characteristics, overall and according to race 
Variable N = 120* White women (n = 80)* Black women (n = 40)* p-value£ 
Age, mean ± SD 55.6 ± 10 55.6 ± 10 55.5 ± 9.9 0.96 
BMI, mean ± SD 28.8 ± 6.2 27.4 31.6 0.0004 
% Density, mean ± SD 30.9 ± 2.1 36.4 ± 1.9 21.5 ± 2.2 0.0006 
2OHE1:16OHE1 EMR,  
mean ± SD 
0.52 ± 0.6 0.54 0.48 0.35 
Family History, n (%) 
No: 97 (81) 
Yes: 19 (16) 
No: 64 (80) 
Yes: 15 (19) 
No: 33 (83) 
Yes: 4 (10) 
0.42ʆ 
Ever Pregnant, n (%) 
No: 23 (19) 
Yes: 91 (76) 
No: 17 (21) 
Yes: 62 (78) 
No: 6 (15) 
Yes: 29 (73) 
0.59 
Number of Live Births, n (%) 
None: 30 (25) 
1 Live Birth: 15 (13) 
2 Live Births: 29 (24) 
3+ Live Births: 40 (33) 
None: 20 (25) 
1 Live Birth: 10 (13) 
2 Live Births: 23 (29) 
3+ Live Births: 26 (33) 
None: 10 (25) 
1 Live Birth: 5 (13) 
2 Live Births: 6 (15) 
3+ Live Births: 14 (35) 
0.60 
OC Use, n (%) 
No: 40 (33) 
Yes: 74 (62) 
No:27 (34) 
Yes: 52 (65) 
No: 13 (33) 
Yes: 22 (55) 
0.76 
Ever Smoke, n (%) 
No: 63 (53) 
Yes: 51 (43) 
No: 48 (60) 
Yes: 31 (39) 
No: 15 (38) 
Yes: 20 (50) 
0.08 
HRT, n (%) 
Never: 48 (40) 
Former: 32 (27) 
Current: 36 (30) 
Never: 32 (40) 
Former: 18 (23) 
Current: 30 (38) 
Never: 16 (40) 
Former: 14 (35) 
Current: 6 (15) 
0.05 
Menopausal Status, n (%) 
Premenopausal: 33 (27.5) 
Postmenopausal: 87 (72.5) 
Premenopausal: 22 (28) 
Postmenopausal: 58 (73) 
Premenopausal: 11 (28) 
Postmenopausal: 29 (73) 
1.00 
* Numbers for some characteristics may not add up due to missing variables; £ p-value: difference between blacks and whites; ʆ 
Fisher‟s Exact between white and black women 
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When the study population was stratified by race, black women had significantly higher 
BMI values than did whites, (31.6 vs. 27.3; p = 0.0004).  A statistically significant difference in 
percent density was also observed between black and white women, with whites having breast 
density 41% higher than that of African Americans (p = 0.0006).  Among white women, there 
was an equal distribution of current and never HRT users, while black women were more likely 
to have never undergone HRT.  No statistically significant differences by race were observed for 
the 2OHE1:16OHE1 EMR, family history of breast cancer, pregnancy status, number of live 
births, OC use, as well as smoking and menopausal status (Table 2). 
Among the predictors of mammographic density, the 2OHE1:16OHE1 EMR was not a 
significantly contributing factor.  The only statistically significant relationships were between 
percent mammographic density and BMI (p = 0.008), and percent mammographic density and 
smoking status (p = 0.002) (Table 3). 
Table 9.  Association between Mammographic Density and demographic variables 
Variable Reference Group Parameter Estimate 95% CI p-value 
2OHE1:16OHE1 EMR 
Continuous 
variable 
-0.11 (-0.74 - 0.52) 0.74 
Age 
Continuous 
variable 
0.002 (-0.05 – 0.06) 0.95 
BMI 
Continuous 
variable 
-0.09 (-0.15 - -0.02) 0.008 
African American Race White -0.61 (-1.46 – 0.24) 0.16 
1+ 1st Degree Relative No family history 0.71 (-0.33 – 1.74) 0.18 
Ever Pregnant Never Pregnant -0.17 (-1.87 – 1.52) 0.84 
1 Live Birth 
No Live Births 
-0.30 (-2.02 – 1.41) 0.73 
2 Live Births -0.23 (-1.87 – 1.40) 0.78 
3+ Live Births -0.52 (-2.10 – 1.07) 0.52 
OC Use Never Use 0.58 (-0.34 – 1.51) 0.21 
Ever Smoker Never Smoke -1.22 (-1.97 - -0.47) 0.002 
Former HRT Use Never HRT Use -0.48 (1.54 – 0.58) 0.37 
Current HRT Use Never HRT Use 0.45 (-0.79 – 1.69) 0.47 
Postmenopausal Premenopausal -0.27 (-1.81 – 1.28) 0.73 
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Stratified analyses did not show a statistically significant association between the 
2OHE1:16OHE1 EMR and mammographic density among white women.  Yet, both BMI and 
smoking were both significantly inversely associated with percent mammographic density (p = 
0.02 and p = 0.007, respectively).  However, none of the variables associated with percent breast 
density in white women resulted in significant relationships with breast density in black women; 
in fact, only BMI showed a weak, non significant inverse association with percent breast density 
(Table 4). 
Table 10.  Association between Mammographic Density and demographic variables 
Stratified by Race 
 White Women Black Women 
Variable 
Parameter 
Estimate 
p-value 95% CI 
Parameter 
Estimate 
p-value 95% CI 
2OHE1:16OHE1 EMR 0.13 0.71 (-0.57 – 0.83) -1.18 0.26 (-3.28 – 0.92) 
Age 0.005 0.89 (-0.06 – 0.07) 0.05 0.45 (-0.13 – 0.24) 
BMI -0.09 0.02 (-0.16 - -0.01) -0.13 0.09 (-0.28 - -0.02) 
1+ 1st Degree Relative  0.62 0.30 (-0.56 – 1.80) 1.56 0.30 (-1.47 – 4.59) 
Ever Pregnant -0.65 0.58 (-2.95 – 1.66) 2.87 0.17 (-1.29 – 7.04) 
1 Live Birth -0.03 0.98 (-2.38 – 2.31) -2.15 0.29 (-6.24 – 1.94) 
2 Live Births -0.38 0.77 (-2.55 – 1.89) -1.40 0.47 (-5.36 – 2.56) 
3+ Live Births -0.80 0.48 (-3.02 – 1.43) -1.31 0.47 (-5.01 – 2.39) 
OC Use 0.63 0.21 (-0.37 – 1.64) 0.19 0.90 (-2.82 – 3.20) 
Ever Smoker -1.23 0.007 (-2.10 - -0.35) -0.61 0.54 (-2.66 – 1.44) 
Former HRT Use -1.56 0.82 (-1.54 – 1.23) -0.67 0.57 (-3.11 – 1.76) 
Current HRT Use 0.45 0.54 (-1.0 – 1.89) 1.35 0.48 (-2.53 – 5.22) 
Postmenopausal -0.38 0.68 (-2.22 – 1.46) -1.04 0.61 (-5.24 – 3.15) 
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4.5 DISCUSSION 
In this study, no significant association with percent mammographic density and serum 
concentrations of the 2OHE1:16OHE1 EMR were observed in the total study population.  To our 
knowledge, the current literature only presents two studies that have analyzed the connection 
between mammographic density and urinary levels of the 2OHE1:16OHE1 EMR.  In 2001, Riza, 
dos Santos Silva, Stavola, et al conducted a large cross-sectional study of healthy, 
postmenopausal women from Halkidiki, Northern Greece.  Utilizing the mammographic density 
classification system developed by Wolf (1976), the authors observed that women with P2/DY 
mammographic patterns were associated with higher urinary 2OHE1:16OHE1EMRs (Riza et al., 
2001).  Another study by Yong, Atkinson, Newton, et al. analyzed a group of healthy 
premenopausal women who were not currently using exogenous hormones.  Urinary 16OHE1 
was found to have a borderline association with percent breast density while 2OHE1 and the 
2OHE1:16OHE1 EMR did not reach statistical significance (Yong et al., 2009).  Differences 
between our results and the two published studies could be methodological in nature, as serum 
estrogen metabolites were measured in the current study, as opposed to urinary levels, however, 
these differences could also be due to sample size issues. 
In our study, the stratified analyses by race did not show any association between the 
2OHE1:16OHE1 EMR and mammographic density in either white or black women.  However, 
among black women there was a non-significant negative relationship between the 
2OHE1:16OHE1 EMR and percent mammographic density, compared to a positive relationship 
observed among white women.  This suggests that estrogens and its metabolites may affect 
mammographic density, and indirectly breast cancer, differently between these two 
subpopulations. 
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Previous studies (Riza and Yong) did not evaluate the association mammographic density 
and the 2OHE1:16OHE1 EMR in black women, therefore to our knowledge, this is the first 
attempt to examine this association.  While the relationship between mammographic density and 
breast cancer risk has been confirmed among white women, there is a lack of evidence 
supporting the association between mammographic density and breast cancer in black women.  
An early case-control study reported no difference in percent mammographic density between 
black cases and controls.  Furthermore, the effect modification by race did not reach the level of 
statistical significance (Ursin et al., 2003).  Another study demonstrated no difference in percent 
mammographic density between black and white women, but did report that black women had 
much higher absolute mammographic density than did white women between the ages of 35-64 
years.  However, these findings do not reflect the difference in breast cancer risk that is present 
between black and white women around 40-45 years of age (Chen et al., 2004).  Similar results 
were observed in another more recent study (Habel et al., 2007).  These findings support the 
necessity for future research to continue to unravel the biologic mechanism of mammographic 
density and to evaluate the role of race to determine whether the effects of mammographic 
density are the same in all women.  Additionally, factors that significantly contribute to 
mammographic density should be analyzed by race, in order to develop an accurate risk profile. 
Overall, the results of the current study demonstrated a significant association between 
BMI and percent mammographic density.  Percent mammographic density has been consistently 
demonstrated to be inversely associated with body weight (N. F. Boyd et al., 2009; Boyd et al., 
2005; Martin & Boyd, 2008; Vachon et al., 2000).  One possible explanation is that as BMI 
increases the amount of fat (non-dense tissue) increases, thereby increasing total breast area 
while the area of dense tissue remains the same or progresses more slowly (Vachon et al., 2000).  
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This hypothesis was supported by a study of premenopausal women, in which weight was found 
to be positively associated with areas of non-dense and total breast area, and negatively 
associated with areas of dense tissue (Boyd et al., 1998).  Similar to our results, in a study 
evaluating the relationship between mammographic density and breast cancer risk among both 
pre and postmenopausal women, an inverse relationship between breast density and BMI was 
also reported (Vacek & Geller, 2004).  This finding was duplicated in a similar study of 
postmenopausal women by Tamimi in 2005 (Tamimi et al., 2005). 
As obesity is a significant risk factor for breast cancer risk among postmenopausal 
women, some evidence suggests that this relationship may be due, in part, to the increase in 
endogenous estrogen exposure that occurs with increasing body weight (Baglietto et al., 2008).  
It is therefore feasible to hypothesize that obesity may alter breast cancer risk through 
mammographic density; however, the relationship between estrogen exposure and 
mammographic density remains unclear.  Some studies have indicated significant inverse 
associations between estrogens and mammographic density, while others report significant 
positive associations (Aiello et al., 2005; Greendale et al., 2005; Johansson et al., 2008).  In a 
study designed to evaluate the relationship between mammographic breast density, circulating 
hormone levels, and clinical breast cancer risk factors, a subgroup of women who‟s BMI fell 
below the study population median had significantly lower estradiol levels and significantly high 
breast density, suggesting that the inverse association between BMI and breast density is 
mediated by estrogens (Johansson et al., 2008).  Conversely, other studies did not confirm the 
association between endogenous hormone concentrations and mammographic density, thereby 
implying that the effect of obesity on breast cancer risk is independent of mammographic density 
(Boyd et al., 2002; Tamimi et al., 2007; Verheus et al., 2007; Warren et al., 2006).  With an 
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incomplete understanding of the biological relationship between mammographic density and 
breast cancer risk, it is plausible that both obesity and mammographic density are associated with 
breast cancer via two separate pathways. 
The current study also supports a significant association between smoking and percent 
mammographic density.  This finding is consistent with reports that identify some components of 
tobacco smoke as anti-estrogenic, which may function by inhibiting gonadotrophin releasing 
hormone and aromatase activity, as well reducing cell proliferation, and increasing estrogen 
metabolism in a manner that produces metabolites with anti-estrogenic properties (Bremnes, 
Ursin, Bjurstam, & Gram, 2007; Butler et al., ; Jeffreys, Warren, Gunnell, McCarron, & Smith, 
2004; Modugno, Ngo et al., 2006). 
When taking race into account, among white women, both smoking and BMI were 
significantly associated with percent mammographic density.  Yet, these results were not 
significant predictors among black women.  To our knowledge, the relationship between 
smoking and mammographic density in black women has yet to be explored. 
While this study presents novel relationships in a rarely studied subpopulation, this study 
is subject to several limitations.  Self-selection bias may be present as participants of MAMS 
were recruited from Magee Women‟s hospital, and its other satellite locations, and were 
subsequently selected on a voluntary basis.  Hence, it is likely that these women may have only 
represented those who take an active approach to health, which limits the generalizability of 
these results to the general population.  Other limitations include reporting and recall bias, due to 
the use of self-reported questionnaires.  Additionally, due to small sample sizes, the power of 
detection was limited, as well as our ability to accurately investigate the role of race. 
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In conclusion, the current study presents for the first time, an analysis of mammographic density 
and the 2OHE1:16OHE1 EMR, in white and black women, and examines predictors of breast 
density separately for the two races.  Our data suggests that serum concentrations of the 
2OHE1:16OHE1 EMR are not associated with percent mammographic density.  However, among 
white women, both BMI and smoking significantly contributed to percent mammographic 
density, a finding that is not confirmed in black women.  These findings provide support to 
further investigate the relationship between estrogen exposure, as well as the 2OHE1:16OHE1 
EMR, and mammographic density, to gain a better understanding of their biological relationship, 
as well as how these factors vary by race, and ultimately how they affect breast cancer risk. 
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5.1 ABSTRACT 
Purpose:  Evidence suggests that the in situ production of estrogen plays a significant 
role in breast physiology.  This local production of hormone termed, “intracrine,” exerts its 
effects within the cells in which it is produced, thereby requiring only modest amounts of 
hormones to elicit a maximum effect.  The objective of this study was to determine the 
2OHE1:16OHE1 estrogen metabolite ratio (EMR) in normal and tumor cell lines derived from 
African American and Caucasian women, and to assess the effects of estradiol treatment on this 
ratio.  Methods:  Five breast epithelial cell lines were purchased from American Type Culture 
Collection (ATCC), and two from Cell Applications.  There were five breast cancer cell lines, 
two of which were derived from African American women (MDA-MB-468 and MDA-MB-157) 
and three from Caucasian women (CAMA-1, SK-BR-3, and ZR-75-1).  The remaining two cell 
lines were normal breast epithelial from Caucasian women (184B5 and HMEpC).  Estrogen 
metabolite levels were quantified using Liquid – Chromatography Mass Spectrometry.  Results:  
The 2OHE1:16OHE1 EMR was relatively stable across all passages of each sample.  In fact, 
passage number was the only significant contributor to the 2OHE1:16OHE1 EMR.  We did not 
observe any significant differences in the 2OHE1:16OHE1 EMR between cell lines derived from 
African American and Caucasian women, normal and tumor breast epithelial cell lines, or 
estradiol treatment.  Conclusions:  The 2OHE1:16OHE1 EMR may not be influenced by external 
factors, such as estrogen exposure but by intrinsic factors that induce subcellular changes, such 
as cellular aging or alterations that differentiate tumor from normal cells, (i.e., genetic variation). 
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5.2 INTRODUCTION 
“Intracrinology” describes a mechanism of action in which hormones are synthesized and 
act on the same cells in which they are produced, without release into the extracellular space or 
into the general circulation (Foster, 2008; Kuhn-Velten, 2000; Sasano et al., 2008).  This 
alternative to classic endocrinology was discovered when dihydrotestosterone (DHT) was found 
in the prostates of men with prostate cancer who had recently undergone castration or androgen 
deprivation therapy.  Scientists observed that while testosterone levels in the blood dropped some 
90-95%, concentrations of active DHT found in the prostate were only reduced by about 50% 
(Labrie et al., 2000).  Since this time, many have attempted to ascribe this type of hormone 
production to other hormone-dependent malignancies. 
Breast cancer is the most common, noncutaneous, cancer among women in the United 
States, with a lifetime risk of 12% and a 5% risk of death (American Cancer Society, 2009; 
Foster, 2008; National Cancer Institute, 2008b).  Nearly two-thirds of all breast cancer cases 
occur during the postmenopausal period, when the ovaries have stopped producing estrogen 
(Pasqualini et al., 1996).  However, evidence suggests that estrogens continue to be produced in 
extragonadal sites, such as adipose tissue, breast, brain, skin, osteoblasts and chondrocytes of 
bone, vascular endothelium, and aortic smooth muscle cells (Foster, 2008; Sasano et al., 2006; 
Simpson, 2003).  Many have reported that aromatase, the enzyme responsible for the conversion 
of androgens to estrogens in the ovary, is expressed in a number of cell types in the breast.  
Immunolocalization revealed aromatase activity in the epithelial cells of ducts in the terminal 
ductal lobular units (TDLU) of normal breast tissue, and in the stromal cells as well as adjacent 
adipose tissue of breast carcinoma (Brodie et al., 1997; Sasano, Nagura, Harada, Goukon, & 
Kimura, 1994; Suzuki, Miki, Ohuchi, & Sasano, 2008). 
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The literature also suggests that while postmenopausal women have low circulating 
levels of estrogen, these concentrations are much higher in normal and tumor breast tissue of 
these women (Brodie et al., 1997; Chetrite, Cortes-Prieto, Philippe, & Pasqualini, 2007; Foster, 
2008; Miettinen et al., 2000).  In fact, it has been reported that the quantity of estradiol acquired 
from the circulation does not significantly contribute to the estradiol concentrations in breast 
tumors, as this estrogen largely originates from de novo biosynthesis.  Furthermore, it has been 
reported that estradiol levels in breast cancer epithelium do not differ by menopausal status, 
despite the fact that plasma estradiol levels decrease approximately 90% after the onset of 
menopause (Billich, Nussbaumer, & Lehr, 2000; Russo, Lareef, Balogh, Guo, & Russo, 2003b; 
Suzuki et al., 2008).  Therefore, it appears that intracrine action may be a significant contributor 
to the development of breast cancer. 
While most epidemiological studies assess the association between estrogens and breast 
cancer risk utilizing serum or plasma estrogen levels, in this study we have evaluated this 
relationship using established breast epithelial cell lines.  In studies assaying serum and/or 
plasma estrogen levels, the ratio of two catcholestrogens, 2-hydroxyestrone (2OHE1) and 16α–
hydroxyestrone (16OHE1), has been implicated as a marker of breast cancer risk.  2OHE1 is 
reported to possesses anti-estrogenic properties, while 16OHE1 is said to be highly estrogenic 
(Lewis, Thomas, Klinge, Gallo, & Thomas, 2001).  The 2OHE1:16OHE1 estrogen metabolite 
ratio (EMR) therefore regulates the proportion of anti-estrogenic molecules to estrogenic ones, 
leading to the hypothesis that women who metabolize estrogen primarily through the 2OHE1 
pathway have a lower risk of developing breast cancer, while those who metabolize estrogens 
primarily through the 16OHE1 pathway, are at an increased risk of developing breast cancer.  
Therefore, the purpose of this study was to assess the association between the 2OHE1:16OHE1 
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EMR and breast cancer risk, in breast epithelial cells.  This novel in vitro assay was conducted in 
seven breast epithelial cell lines, utilizing both tumor and normal cells, derived from African 
American and Caucasian women, to determine if differences in the 2OHE1:16OHE1 EMR exists 
by race, cell type (tumor or normal), estradiol treatment, or passage number. 
5.3 MATERIALS AND METHODS 
5.3.1 Cell Lines and Chemicals 
Seven human breast epithelial cell lines were purchased to conduct this experiment; five (MDA-
MB-468, MDA-MB-157, CAMA-1, SK-BR-3, and ZR-75-1) from ATCC (ATCC, Manassas, 
Virginia), and two (184B5 and HMEpC) from Cell Applications (Cell Applications, San Diego, 
California).  Five of the seven cell lines, were breast tumor tissue, two from African American 
women (MDA-MB-468 and MDA-MB-157) and three from Caucasian women (CAMA-1, SK-
BR-3, and ZR-75-1).  The remaining two cell lines were normal breast epithelial, originating 
from Caucasian women that underwent breast reduction mammoplasty (184B5 and HMEpC).  
Each cell line was cultured according to the manufacturer‟s specified instructions and 
subcultured in T-75 flasks.  MDA-MB-157 and MDA-MB-468 cell lines were propagated 
utilizing Leibovitz‟s L-15 Media, supplemented with 1.5mM L-glutamine and 2200 mg/L 
sodium bicarbonate, 10% fetal bovine serum (FBS), and maintained at 37ºC with 100% air.  The 
CAMA-1 cell line was cultured in Eagle‟s Minimal Essential Media, supplemented with non-
essential amino acids, 2mM L-glutamine, 1mM sodium pyruvate, 1500mg/L sodium bicarbonate, 
10% FBS, and maintained at 37ºC with 5% CO2.  SK-BR-3 was propagated in McCoy‟s 5A 
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Medium, supplemented with 1.5mM L-glutamine and 2200mg/L sodium bicarbonate, 10% FBS, 
and kept at 37ºC with 5% CO2.  ZR-75-1 was cultured using RPMI – 1640 media, supplemented 
with non-essential amino acids, 2mM L-glutamine, 1mM sodium pyruvate, 1500 mg/L sodium 
bicarbonate, 10% FBS, and maintained at 37ºC with 5% CO2.  The 184B5 and HMEpC cell lines 
were cultured in serum free Mammary Epithelial Cell Basal Medium, purchased from Cell 
Applications, Inc (Cell Applications, San Diego, CA). 
17β–estradiol was purchased from Sigma Aldrich (Sigma Aldrich, Saint Louis, MA), and 
was reconstituted in distilled water for a final concentration of 5nM.  All cell lines were 
subcultured approximately every 2 to 3 days, and grown to about 40 to 45% confluence in an 
effort to keep the passage numbers of all cell lines in unison with one another. After the 
appropriate confluence was attained for each cell line, half the number of flasks accumulated for 
each cell line were treated with 0.75µl of reconstituted estradiol along with fresh media, while 
the other half received only fresh media.  Seventy-two (72) hours after the administration of 
estradiol treatment, the media was aspirated from the cells and washed with 5ml of Phosphate 
Buffered Saline (PBS).  The cells were then trypsinized, harvested, and centrifuged at 1600 rpm 
for 5 minutes at 4ºC.  Media from the cell pellet was aspirated, and the pellet was rinsed with 5 
ml of PBS, and centrifuged again at 1600rpm for 5 min at 4ºC.  The PBS was aspirated, and the 
pellet was stored at -20ºC. 
5.3.2 Liquid Chromatography-Mass Spectrometry 
Catecholestrogens were quantified utilizing Liquid Chromatography–Mass Spectrometry (LC–
MS) in the laboratory of Dr. Timothy Veenstra, at the National Institutes of Health (Bethesda, 
MD).  Each cell pellet was re-suspended in 0.5 ml of 25 mM sodium acetate buffer (pH 4.6), and 
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5µL dEM (8µg/µL) internal standard solution.  The re–suspended pellet was then vortexed for 10 
seconds, and placed in a sonicating water bath for 30 minutes.  For an additional 30 seconds, tip 
sonication was used in 10 second intervals.  Then, 0.5mL of 150mM sodium acetate buffer (pH 
4.6), containing 1mg L-ascorbic acid, 5µL β-glucuronidase, and sulfatase enzyme mixture was 
added.  The sample was then incubated at 37°C for approximately 20 hours.  Following 
incubation, the sample was transferred to a screw-capped glass test tube, to undergo extraction 
with 6 mL dichloromethane.  The dichloromethane was dried with N2 gas and dansylated.  
Lastly, tandem mass spectrometry with selected reaction monitoring, coupled with baseline 
liquid chromatography was conducted, thereby significantly increasing the specificity of the 
measurement. 
This methodology has a lower limit of quantitation (LLOQ) of 25 fg on column (in 1/10 
of the cell pellet) for each estrogen.  The LLOQ is the lowest level of estrogen that can reliably 
be measured with excellent accuracy and precision.  The limit of detection (LOD) for this study 
was 1 fg on column (in 1/10 of the cell pellet) for each estrogen.  The LOD represents the target 
estrogen peak that has a signal-to-noise ratio greater than three.   
5.3.3 Statistical Analysis 
All analyses were conducted utilizing SAS version 9.2 (SAS Institute, Cary, North Carolina) 
software, with an alpha level of 0.05. Due to the various growth patterns and properties of each 
cell line, numerous passages were attained while subculturing.  A total of 138 observations were 
collected and analyzed, representing between 14 and 22 for each sample.  Exploratory analysis 
showed that the 2OHE1:16OHE1 EMR was relatively stable across passage numbers (Figure 4).  
Considering this, actual passage numbers were utilized as covariates in the models. 
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Figure 4.  2OHE1:16OHE1 EMR Distribution by Passage Number 
Quantification of the catecholestrogens by LC-MS provided individual data for each 
estrogen metabolite, for each culture flask examined.  The 2OHE1:16OHE1 EMR was calculated 
using the individual data for 2OHE1 and 16OHE1, respectively, and revealed a highly skewed 
distribution.  Therefore, a log transformation of 2OHE1:16OHE1 EMR was conducted to 
normalize the data.  Parametric statistical testing was utilized for all univariate analyses. 
To assess the effects of cell type, estradiol treatment, passage number, and race on the 
2OHE1:16OHE1 EMR, mixed linear modeling was utilized to account for both fixed effects 
(treatment, passage number, and cell type) and repeated measures (cell lines).  The first model 
consisted of all cell lines derived from Caucasian women to assess the effects of cell type, 
estradiol treatment, and passage number on the 2OHE1:16OHE1 EMR, while the second was 
comprised of all breast carcinoma cell lines, to evaluate the effects of race, treatment, and 
passage number on the 2OHE1:16OHE1 EMR (Figure 5). 
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Figure 5.  Mixed Linear Model Designs 
5.4 RESULTS 
Table 13 contains a detailed description of all cell lines analyzed.  To assess mean differences 
between the logged 2OHE1:16OHE1 EMR of treated and untreated cells for each cell line, two-
sample t-tests were conducted.  Our results demonstrated that there were no significant 
differences in the logged mean 2OHE1:16OHE1 EMR of treated and untreated cells within the 
same cell lines. 
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Table 11.  Cell Line Characteristics 
 Untreated Treated  
Cell Line Race£ Age 
Cell 
Type¥ 
Tumor Type 
ER 
Status 
Mean 
EMR• 
Mean 
EMR• 
p value* 
HMEpC C 21 N n/a n/a 43.38 61.56 0.53 
184B5 C 21 N n/a n/a 262.43 204.38 0.39 
CAMA-1 C 51 T Adenocarcinoma + 104.58 81.45 0.61 
SK-BR-3 C 43 T Adenocarcinoma - 139.77 100.48 0.29 
ZR-75-1 C 63 T Ductal carcinoma + 101.49 121.51 0.62 
MDA-MB-157 A 44 T 
Medullary 
carcinoma 
- 111.05 107.77 0.93 
MDA-MB-468 A 51 T Adenocarcinoma - 127.74 129.02 0.99 
£ C: Caucasian derived cell lines; A: African American derived cell lines, ¥ N: Normal cell lines; T: Tumor cell lines, 
• Mean has been untransformed for easy interpretation, *Difference in mean EMR of untreated and treated cell lines 
 
Univariate analyses were also conducted to identify potential differences that may exist 
within each independent categorical variable (Table 14).  These variables were then stratified to 
identify other possible differences in the logged mean 2OHE1:16OHE1 EMR.  Neither the initial 
univariate nor stratified analyses revealed any statistically significant differences in the logged 
mean 2OHE1:16OHE1 EMR by race, cell type, or estradiol treatment. 
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Table 12.  Univariate Analyses 
Variable 2OHE1:16OHE1 EMR
• p - value 
Race African American: 120.30 Caucasian: 111.05 0.67 
Cell Type Tumor: 111.05 Normal: 117.92 0.78 
Treatment Level Treated: 111.05 Untreated: 116.75 0.76 
Normal Only Treated: 117.92 Untreated: 117.92 1.0 
Tumor Only 
African American: 120.30 Caucasian: 106.70 0.57 
Treated: 107.77 Untreated: 115.58 0.69 
Treated Cells Only 
African American: 119.10 Caucasian: 106.70 0.69 
Tumor: 107.77 Normal: 117.92 0.73 
Untreated Cells Only 
African American: 122.73 Caucasian: 114.43 0.86 
Tumor: 115.58 Normal: 117.92 0.97 
• Mean has been untransformed for easy interpretation 
The results of our mixed linear modeling can be found in Table 15.  In both unadjusted 
models, significant positive associations between passage number and the 2OHE1:16OHE1 EMR 
were observed.  This finding remained once all models were adjusted for all covariates (cell type, 
estradiol treatment, passage number, and race).  Additionally, both unadjusted models revealed 
negative relationships between estradiol treatment and the 2OHE1:16OHE1 EMR.  However, this 
effect was not seen in adjusted model 2; in fact, in this model, estradiol treatment and the 
2OHE1:16OHE1 EMR were positively associated.  The results of the first unadjusted model, 
demonstrated a negative association between cell type and the 2OHE1:16OHE1 EMR, yet in the 
adjusted model there was positive association was observed.  On the other hand, there was a 
positive relationship between race and the 2OHE1:16OHE1 EMR, an effect that remained in the 
adjusted models as well.  However, the findings of cell type, treatment, and race did not reach 
statistical significance. 
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Table 13.  Mixed Linear Model Results 
 
Additional exploratory analysis was also conducted to assess the effect of estrogen 
receptor (ER) status on the 2OHE1:16OHE1 EMR in the five breast cancer cell lines.  A two-
sample t-test was conducted to evaluate differences in the logged mean 2OHE1:16OHE1 EMR 
between ER positive (ER+) and ER negative (ER-) cell lines.  However, no significant difference 
Mixed Linear Design Model 1 
(unadjusted) 
Variable Parameter Estimate p-value 
Cell Type -0.03359 0.96 
Treatment -0.06840 0.71 
Passage 0.07327 0.05 
Mixed Linear Design Model 2 
(unadjusted) 
Treatment -0.06643 0.75 
Race 0.1482 0.26 
Passage 0.2146 0.004 
Mixed Linear Design Model 1 
(adjusted) 
Variable Parameter Estimate p-value 
Cell Type 0.06041 0.93 
Treatment -0.1008 0.58 
Passage 0.07775 0.04 
Mixed Linear Design Model 2 
(adjusted) 
Treatment 0.05800 0.7783 
Race 0.02654 0.9055 
Passage 0.02365 0.004 
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was observed (Table 16).  When this variable was added to our mixed linear model, it still did 
not reach statistical significance in either unadjusted or adjusted models (Table 17). 
Table 14.  Univariate Analysis of ER Status 
Variable 2OHE1 : 16OHE1 EMR p – value
** 
ER Status ER+ : 101.49 ER- : 120.30 0.38 
 
 
Table 15. Mixed Linear Model Results 
Mixed Linear Design Model 2 
(unadjusted) 
Variable Parameter Estimate p - value 
ER Status -0.01756 0.15 
Mixed Linear Design Model 2 
(adjusted) 
Treatment 0.06819 0.74 
Race -0.02580 0.34 
Passage 0.2520 0.002 
ER Status 0.3791 0.19 
 
5.5 DISCUSSION 
While many studies have assessed total estrogen concentrations in cell culture, to our 
knowledge, no other study has quantified the 2OHE1:16OHE1 EMR, nor has any study evaluated 
potential racial differences in culture.  Evidence suggests that the concentration of estrogen, 
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specifically estradiol, in tumor tissues is much higher than that of normal breast tissue (Chetrite, 
Cortes-Prieto, Philippe, Wright, & Pasqualini, 2000; Miettinen et al., 2000; Miller, Hawkins, & 
Forrest, 1982; Suzuki et al., 2008).  While we were unable to replicate this effect, we did observe 
significant positive associations between passage number and the 2OHE1:16OHE1 EMR.   
Passage number generally refers to the number of times a cell line has been subcultured 
into a new flask (American Type Culture Collection, 2007).  It has been reported that over-
subculturing cell lines, resulting in high passage numbers, can elicit adverse property changes 
that range from alterations in anitigenicity, pathogenicity, cell morphology, growth rates, protein 
expression, signaling, transfection, and response to stimuli (American Type Culture Collection, 
2007; Peterson, Tachiki, & Yamaguchi, 2004; Scott, Connor, Creelan, McNulty, & Todd, 1999).  
However, terms such as „high‟ and „low‟ passage are very subjective, as they vary by cell line, 
since there is no established methodology of determining the actual passage number (American 
Type Culture Collection, 2007).  However, we have no reason to believe that we have over-
subcultured our samples. 
It is reasonable to examine the effects of passage number, as they may be equated with 
the aging process.  A study by Peterson, Tachiki, and Yamaguchi (2004), examined MC3T3-E1 
cells to study the effects of senescence on proliferation during osteogenesis in vitro which may 
be reflective of this process in vivo.  The authors observed a 2-fold decrease in cell proliferation 
in cells at passage 42 after 11 days in culture, and also reported an overall decrease in population 
doubling after passage number 36 (Peterson et al., 2004).  As aging decreases bone formation, 
studies such as these are very informative. 
To date, only two studies have evaluated the relationship between age and the 
2OHE1:16OHE1 EMR, one of which did not observe a significant relationship (Kabat et al., 
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1997).  However, we have previously reported a significant positive relationship with age and the 
2OHE1:16OHE1 EMR (Lloyd, Taioli, Chen, Arhendt, Feingold, and Garte, 2010).  Increasing 
age has previously been identified as a significant risk factor for breast cancer, as; in general, 
aging has been reported to increase genomic instability, induce global and promoter-specific 
epigenetic changes, and to alter the expression of genes involved in cell division and 
extracellular matrix remodeling (Yau et al., 2007).  While we did not explicitly evaluate the 
effects of increasing passage numbers on the 2OHE1:16OHE1 EMR in these cell lines, our study 
design has permitted us to observe this association, and warrants further investigation. 
While the objective of this study was to evaluate differences in the 2OHE1:16OHE1 EMR 
in normal and tumor breast epithelial cell lines, the majority of in vitro studies focus primarily on 
the biosynthesis of estrogen in culture.  The formation of estrogen occurs through two major 
pathways; the aromatase pathway, which is responsible for the conversion of androgens 
(androstenedione) to estrogens (estrone), and the sulfatase pathway, which is responsible for the 
conversion of estrone sulfate to estrone, the parent substance of 2OHE1 and 16OHE1 (Chetrite et 
al., 2000; Nelson & Bulun, 2001; Sasano, Nagasaki, Miki, & Suzuki, 2009; Sasano et al., 2006).  
Aromatase activity has been detected in both normal and breast tumors, whereas sulfatase 
activity is reported to have activity levels 50 times greater in breast tumors compared to normal 
breast tissue, and has been detected in 90% of breast tumors (Foster, 2008; Miettinen et al., 2000; 
Pasqualini & Chetrite, 1999; Sasano et al., 2006; Suzuki et al., 2003).  A study by Chertrite, 
Cortes-Prieto, et al. (2007) observed that the conversion of estrone sulfate to estrone was 7-10 
times higher in the tumors of postmenopausal women with breast cancer than in morphologically 
normal tissue of the same patient.  Furthermore, this study also found that the presence of 
estradiol exhibited an inhibitory effect on the enzymatic activity of estrone sulfate.  The 
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conversion of estrone sulfate to estradiol was not observed in either tissue sample, however, the 
conversion of estrone sulfate to estrone could still be detected in both, normal and tumor tissue.  
Yet, the production of estrone was much greater in tumor than in normal tissue (Chetrite et al., 
2007). 
Given that 33-50% of all breast cancers respond to estrogen treatment, we evaluated the 
effect of estrogen receptor status on tissue concentrations of the 2OHE1:16OHE1 EMR 
(Pasqualini et al., 1996).  However, we did not find any significant results.  This finding is 
consistent with a study that assessed the correlation between ER status, and tissue concentrations 
of estrone, estradiol, estrone sulfate, estradiol sulfate, as well as aromatase and sulfatase 
enzymatic activities in postmenopausal women.  The authors reported not observing any 
correlations between ER status and tissue concentrations of estrogens or the enzymatic activities 
of aromatase and sulfatase (Chetrite et al., 2000).  This, as well as our findings suggests that ER 
status may not play a significant role in the local production of estrogen. 
Intracrinology is a fairly new area of research, yet the theory on which this mechanism of 
action is based, has benefited numerous postmenopausal women with breast cancer.  For the past 
25 years, aromatase inhibitors have been used as one treatment method for metastatic breast 
cancer (Howell & Buzdar, 2005).  It has been reported that the concentration of estradiol in the 
tumors of postmenopausal women is 20-fold greater than what is found in the plasma.  However, 
administration of aromatase inhibitors produce a significant decline in intratumoral estradiol, 
estrone, and aromatase activities (Simpson, 2003).  These results not only support the 
Intracrinology hypothesis, but also emphasize the importance of the local production of estrogen 
to the growth and progression of breast cancer. 
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While most studies focus primarily on the concentrations of estradiol and estrone, it is 
important to note that 2OHE1 and 16OHE1 are the most significant metabolites of estradiol.  
They are believed to function as signaling molecules; have variable binding affinities for the ER; 
are capable of covalently binding DNA and forming DNA adducts; and appear to be more 
mutagenic than their parent compound (Jefcoate et al., 2000; Liehr, 2001; Roy & Liehr, 1999).  
The ratio of these two catecholestrogens, has been implicated as marker of breast cancer risk in 
studies assaying plasma and serum, therefore the purpose of this study was to evaluate tissue 
concentrations of the 2OHE1: 16OHE1 EMR in cell culture, to determine if differences in race, 
cell type, and estradiol treatment could be detected.  An analysis of this sort is very interesting, 
as it allows us to examine the disparity among African American women at the cellular level, as 
any differences found here would indicate that these women may metabolize estrogens 
differently from Caucasian women. 
One limitation of this study was the use of FBS as part of the growth medium in the 
breast cancer cell lines.  While the exact estrogen concentration in the FBS is unknown, we are 
satisfied with our findings, as levels of 2OHE1 and 16OHE1 were assayed directly from the cells 
themselves.  Additionally, all cells were washed thoroughly with PBS before trypsinization, and 
were washed again after centrifugation.  Therefore, we have no reason to believe that the 
administration of FBS would in any way, bias our results.  Another limitation of this study was 
the inability to obtain normal breast epithelial cell lines from African American women, which 
would have allowed for better comparisons by race, and better overall analysis of differences by 
cell type. 
In conclusion, these findings suggest that the process of cellular aging, rather than 
estrogen exposure, may be associated with alterations in the 2OHE1:16OHE1 EMR in breast 
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epithelial cells.  As this was a novel investigation, and no significant associations between cell 
type, estradiol treatment, or race were observed, some of our findings were supported by the 
literature, warranting further investigation. 
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6.0  AN ANALYSIS OF ESTROGEN METABOLISM AND BREAST CANCER RISK 
DISCUSSION 
Again, the overall objective of this study was to investigate the association between the 2OHE1: 
16OHE1 EMR, the CYP1B1 Leu432Val polymorphism, mammographic density, race, and breast 
cancer risk, to illustrate whether or not variation in estrogen metabolism was associated with 
differences in breast cancer risk.  The results of this study were also designed to highlight a 
potential biological explanation for the disparity in breast cancer morbidity and mortality 
between African American and Caucasian women.  We therefore, hypothesized that women who 
metabolized estrogen primarily through the 16OHE1 pathway would have an increased risk of 
developing breast cancer. 
Our first analysis evaluated the effects of the CYP1B1 Leu432Val polymorphism on the 
urinary 2OHE1:16OHE1 EMR and breast cancer risk.  As the CYP1B1 gene catalyzes the 
formation of both 2OHE1 and 16OHE1, we hypothesized that the presence of the variant, valine, 
allele of this polymorphism may negatively alter the effect of the 2OHE1:16OHE1 EMR, which 
in turn, may negatively alter breast cancer risk.  The results of this study demonstrated a 
significant association between the 2OHE1:16OHE1 EMR and breast cancer, but did not reveal 
any associations among the CYP1B1 genotype and breast cancer risk.  Conversely, the 
relationship between the 2OHE1:16OHE1 EMR and the CYP1B1 genotype did reach statistical 
significance.  Once these results were stratified by case-control status, we observed that this 
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association was only significant among our control population.  Based on the results of this 
study, as well as evidence in the literature that supports the hypothesis that the CYP1B1 genotype 
is associated with breast cancer risk, we can tentatively conclude that the CYP1B1 Leu432Val 
polymorphism may indirectly influence breast cancer risk, by altering the 2OHE1:16OHE1 EMR 
(Kocabas et al., 2002; Paracchini et al., 2005; Paracchini et al., 2007; Rylander-Rudqvist et al., 
2003). 
When evaluating the role of race in the relationship between the 2OHE1:16OHE1 EMR 
and breast cancer risk, we examined the association between this ratio and mammographic 
density in a population of cancer-free pre and postmenopausal women.  As the risk of developing 
breast cancer associated with mammographic density, is greater than the combined risk of all 
other clinical risk factors, this study served as a suitable proxy for assessing the association of 
the 2OHE1:16OHE1 EMR and breast cancer risk (Greendale et al., 2005).  Given the association 
of mammographic density and endogenous, as well as exogenous, estrogen exposure, we 
hypothesized that mammographic density would have a negative association with the 
2OHE1:16OHE1 EMR.  Likewise, as the risk profiles for developing breast cancer varies between 
African American and Caucasian women, we also hypothesized that race would have a negative 
effect on the 2OHE1:16OHE1 EMR.  However, we found that Caucasian and African American 
women in this study population differed only by BMI, HRT use, and mammographic density, but 
not the 2OHE1:16OHE1 EMR.  Furthermore, we did not observe an association between 
mammographic density and the 2OHE1:16OHE1 EMR.  Across the entire study population, the 
only significant predictors of mammographic density were BMI and smoking status, a finding 
that was also duplicated among Caucasian women, but not among African Americans.  Although 
no significant relationships were observed between the 2OHE1:16OHE1 EMR and 
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mammographic density in either race, or in the total population, the results of this study did 
demonstrate differences in factors that contributed to mammographic density.  These findings are 
consistent with reports that denote differences in risk profiles for African American and 
Caucasian women.  For example, Caucasian women are more likely to developed breast cancer 
after the age of 50, while the risk of developing breast cancer for African American women is 
greater under the age of 40 (American Cancer Society, 2008a).  Additionally, African American 
women are more likely to have larger, estrogen negative, high grade tumors (Breastcancer.org, 
2008; Chlebowski et al., 2005; Curtis et al., 2008; Key et al., 2001).  Therefore, we can conclude 
that the 2OHE1:16OHE1 EMR does not appear to affect mammographic density and the factors 
that are associated with mammographic density may vary by race. 
The literature reports that the conversion of androgens to estrogens also occurs in breast 
tissue (Brodie et al., 1997).  This local production of estrogen is termed Intracrine, as that which 
is produced is not released into the bloodstream.  Therefore, this system of hormone production 
is much more efficient in the development of hormone-dependent malignancies, as only modest 
quantities of hormones are needed to elicit a maximum effect (Foster, 2008; Sasano et al., 2008).  
To date, no other study has sought to assess concentrations of the 2OHE1:16OHE1 EMR in breast 
tissue, hence, we conducted an in vitro assay in both normal and tumor breast epithelial cell lines 
to determine 2OHE1:16OHE1 EMR concentrations.  The effects of race and estradiol treatment 
on tissue levels of the 2OHE1:16OHE1 EMR were also examined.  We hypothesized that there 
would be significant differences in the mean 2OHE1:16OHE1 EMR between normal and tumor 
cell lines, as well as significant differences in the mean 2OHE1:16OHE1 EMR in cell lines 
derived from African American versus Caucasian women, and in treated versus untreated cell 
lines.  We also hypothesized that cell type, race, and estradiol treatment would all be significant 
90 
predictors of the 2OHE1:16OHE1 EMR.  As 2OHE1:16OHE1 EMR levels were fairly stable 
across all passage numbers, these numbers were added as an additional covariate.  The results of 
this study revealed that there were no differences in the mean 2OHE1:16OHE1 EMR of normal 
and tumor cell lines, nor between treated and untreated cells, or in cell lines derived from African 
American and Caucasian women.  In fact, the only contributor to the 2OHE1:16OHE1 EMR was 
passage number.  This finding suggests that estrogen exposure alone may not be the underlying 
causative agent in the development of breast cancer, nor does it significantly alter estrogen 
metabolism.  The literature often equates passage number to aging, as a number of sub-cellular 
changes occur with increasing passage number, thereby implying that other intrinsic alterations 
(i.e., genetic variation) may affect the 2OHE1:16OHE1 EMR (American Type Culture 
Collection, 2007; Peterson et al., 2004; Scott et al., 1999). 
The results of this study highlight the complexity involved in assessing the relationship 
between the 2OHE1:16OHE1 EMR and breast cancer risk, as well as determining those risk 
factors that significantly contribute to it.  However, we have successfully demonstrated an 
association between the 2OHE1:16OHE1 EMR and breast cancer risk, with the findings of 
specific aim one.  While these findings should be confirmed, our logistic regression analysis in 
aim one revealed that a high 2OHE1:16OHE1 EMR was associated with a 72% decrease in the 
risk of being a case (p < 0.0012).  Currently, the literature presents a few studies that have 
investigated the association of the urinary 2OHE1:16OHE1 EMR and breast cancer risk as we 
have hypothesized, and have found similar results.  One such study was conducted by Muti, 
Bradlow, Micheli, et al. (2000), in which the authors conducted a nested case-control study of 
both pre- and postmenopausal women, and concluded that among premenopausal women, a high 
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2OHE1:16OHE1 EMR decreases breast cancer risk (Muti et al., 2000).  This result was duplicated 
in 2006 by Kabat, O‟Leary, Gammon et al. (Kabat et al., 1997). 
Upon examination of the relationship between known breast cancer risk factors and the 
2OHE1:16OHE1 EMR, we observed significant associations between age; and the age and BMI 
interaction.  We observed a positive relationship between age and the 2OHE1:16OHE1 EMR in 
our first analysis, as well as a negative association with the age and BMI interaction.  To date, 
we have only identified one other study that examined the relationship between age and the 
2OHE1:16OHE1 EMR, but this study did not observe a consistent relationship (Kabat et al., 
1997).  Nonetheless, these findings can also be extended to our third aim, as passage number was 
the only significant contributor to the 2OHE1:16OHE1 EMR. 
Age is an established risk factor for breast cancer, as, in general, risk for developing 
breast cancer increases with increasing age.  Part of this association is due to the increasing life 
expectancy of Americans, but also includes factors such as long-term postmenopausal hormone 
therapy use due to changes in reproductive patterns (American Cancer Society, 2007).  The 
effects of aging include a myriad of biological changes, from obesity, elevated blood pressure, 
and increasing lipid and lipoprotein levels (Owens, Matthews, Wing, & Kuller, 1992).  Ageing 
has been defined by Kirkwood and Austad (2000) as a, “Progressive loss of function 
accompanied by decreasing fertility and increasing mortality” (p. 233).  However, aging is also a 
complex process that is regulated by several signaling pathways and transcriptions factors, and is 
the subject of several evolutionary debates (Kenyon, ; Kirkwood & Austad, 2000).  One such 
theory, is termed the „accumulation theory‟ which describes the accumulation of late-effect 
deleterious alleles that are unselected for, and thereby exhibit heterogeneous distribution 
throughout the population (Kirkwood & Austad, 2000).  This collection of genetic and epigenetic 
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changes results in macromolecular changes such as decreasing telomere length and dysfunctional 
DNA damage repair processes, which lead to senescence, apoptosis, and loss of replication, all of 
which are similar mechanisms involved in carcinogenesis (Bassi & Sacco, 2009; Neumeister, 
Albanese, Balent, Greally, & Pestell, 2002).  This intricate relationship between aging and 
cancer, may account for the lack of the association observed between the 2OHE1:16OHE1 EMR 
and breast cancer risk in vitro and mammographic density. 
In the current study, we were unable to demonstrate an association between the 
2OHE1:16OHE1 EMR and mammographic density, the most significant risk factor in breast 
cancer etiology.  At the present time, there is no well defined biological mechanism to explain 
the influence of mammographic density on breast cancer risk, however, the results of specific 
aim 2 revealed that mammographic density was associated with factors such as smoking and 
BMI, findings that are supported in the literature (N. F. Boyd et al., 2009; Bremnes, Ursin, 
Bjurstam, & Gram, 2007; Butler et al., ; Jeffreys et al., 2004; Martin & Boyd, 2008; Vachon et 
al., 2000).  Although age was not a significant predictor of mammographic density in this study, 
the literature presents consistent evidence to show that mammographic density does in fact 
decrease with increasing age (N. F. Boyd et al., 2009; Haiman et al., 2003; Vachon et al., 2000; 
Warren, 2004; Woolcott et al., 2009).  As the mean age of this study population was 55.6 and 
most participants were postmenopausal, it is feasible to conclude that the effects of the aging 
may also influence the relationship between mammographic density and breast cancer risk. 
As previously mentioned, there is a positive association between age and obesity, but 
there also exists, in general, a negative association between age and estrogen levels, given the 
onset of menopause significantly decreases circulating estrogen levels (Billich et al., 2000; 
Brodie et al., 1997; Russo, Lareef, Balogh, Guo, & Russo, 2003a).  Obesity has long been 
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considered a risk factor for breast cancer among postmenopausal women, given the increasing 
amounts of estrogen produced by adipose tissue (Baglietto et al., 2008; Clemons & Goss, 2001; 
Dignam et al., 2006).  However, the findings of specific aim 1 demonstrated a non-significant 
positive association between BMI and the 2OHE1:16OHE1 EMR for both cases and controls, and 
yet, a significant negative association was observed between the 2OHE1:16OHE1 EMR and an 
age and BMI interaction among cases, implying that increasing age in conjunction with 
increasing body weight is associated with lower estrogen metabolite levels.  While both age and 
BMI are two highly correlated variables, the literature has reported similar findings between 
BMI and 2OHE1:16OHE1 EMR concentrations.  In a study by Falk, Fears, Xu, et al. (2005), the 
authors observed that among Asian American premenopausal women, a low 2OHE1:16OHE1 
EMR was found among those with a high BMI, >24.6 kg/m2, and an even lower ratio was 
observed among obese women, BMI > 29 kg/m2.  This result was not repeated in 
postmenopausal women (Falk et al., 2005).  However, there are very few studies that investigate 
other known breast cancer risk factors in relation to the 2OHE1:16OHE1 EMR. 
Although our study presents the findings of some novel research, it is also subject to 
several limitations.  A case control study is a useful first step when exploring a source of disease 
(Gordis, 2004).  This study design allowed us to investigate a variety of characteristics that may 
lead to an adverse health outcome.  However, one limitation to utilizing this design is that we 
were unable to obtain the absolute risk (incidence) of disease, nor could we determine the 
relative risk of disease in the study population.  Furthermore, the use of a case-control study 
design that consisted only of Caucasian women prevented applicable comparisons to other 
racial/ethnic groups.  We also observed some dissimilarities between our cases and controls (e.g., 
age and BMI) that make drawing solid conclusions difficult. 
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Selection bias may also have been introduced into our research, as the controls in our 
case-control study were obtained from other studies.  Therefore, the selection, as well as 
exclusion criteria may have differed for each group.  This bias may have also been present in 
specific aim two, as these participants were recruited from Magee Women‟s hospital, and its 
other satellite locations, and were subsequently selected on a voluntary basis.  Hence, it is likely 
that these women may have only represented those who take an active approach to health, which 
limits the generalizability of these results to the general population.  Other limitations include 
reporting and recall bias, due to the use of self-reported questionnaires in specific aim two, and 
small sample sizes, which limited our power of detection. 
Overall, further research is warranted to confirm the results of this study.  However, the 
large majority of examinations assessing the 2OHE1:16OHE1 EMR and breast cancer risk, are 
case – control studies, that do not investigate the contributing factors to the 2OHE1:16OHE1 
EMR.  For this reason alone, our research is a significant contribution to the literature.  
Additionally, few studies have addressed the serum 2OHE1:16OHE1 EMR in premenopausal 
women, and even fewer in African American women.  Specific aim three is a completely novel 
experiment, with significant implications.  Findings from studies such as these may one day 
allow investigators to evaluate the disparity facing African American women on a cellular level, 
to determine if the breasts of these women metabolize estrogens differently from Caucasian 
women.  This project will also enhance the literature regarding the breasts‟ ability to synthesize 
estrogen, by expounding on the area of intracrinology.  Although definitive conclusions cannot 
be made on the basis of this investigation, the uniqueness of our study designs and new results 
will enhance the body of evidence regarding the role of estrogens in breast cancer, and the 
genetics associated with this relationship. 
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Additionally, the current study also provides an indirect assessment of variation in 
concentrations of the 2OHE1:16OHE1 EMR that can be found throughout the body.  This study 
evaluated 2OHE1:16OHE1 EMR concentrations from three different sources: urine, serum, and 
breast epithelial.  Urine is the most common method utilized to assess 2OHE1:16OHE1 EMR 
levels and concentrations in our study ranged from 0.2-5, with an overall mean of 1.95.  On the 
other hand, serum levels of the 2OHE1:16OHE1 EMR was considerably lower, ranging from 0.1-
3, with an overall mean of 0.52, while concentrations assayed directly from breast tissue were 
highest, presenting values from 2.5-865, with an overall mean of 166.15.  To our knowledge, this 
is first study ever to document such differences. 
One goal of this research project was to explore the role of race in our analyses, in hopes 
of highlighting potential differences between African American and Caucasian women, given the 
incidence and mortality disparities between them.  Many suggest that socioeconomic factors are 
largely to blame, citing that these women lack proper access to healthcare and receive inadequate 
treatment after diagnosis.  Yet, studies such as those by Wojcik, Spinks, & Optenberg (1998) and 
Jatoi, Becher, & Leake, (2003) demonstrate that even within an equal access medical system, this 
disparity persists.  Nevertheless, few studies have addressed the association of estrogen and 
breast cancer risk in African American women, but we attempted to do so.  Our study sought to 
determine if there were racial differences in the 2OHE1:16OHE1 EMR.  While we only assessed 
this relationship in two of our aims, we did not observe significant differences in the 
2OHE1:16OHE1 EMR between Caucasian and African American women.  However, we did 
observe evidence to suggest that the predictors of breast cancer risk may differ between African 
American and Caucasian women. 
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Unfortunately, one limitation of this study is that we were unable to explore the role of 
race in all three aims.  This leaves to question whether or not there are differences in the 
2OHE1:16OHE1 EMR among African American and Caucasian populations, and whether this 
ratio alters breast cancer risk in African American women.  Differences found in this type of 
analysis, would further confirm that breast cancer risk factors may have opposing effects in 
racial/ethnic populations.  Furthermore, given the inaccessibility of a variety of tumor and 
normal cell lines from African American women, we were unable to draw any conclusions as to 
whether estrogen metabolism in the breast of these women differs from that of Caucasian 
women.  We suspect that one reason for this lack of association is the large differences in sample 
size. 
Another limitation of this study was the inability to more accurately assess the role of the 
CYP1B1 Leu432Val polymorphism in breast cancer risk, and the role of race in this relationship.  
In the literature we have seen a significant association between breast cancer risk and the 
CYP1B1 Leu432Val polymorphism, but we were unable to confirm these findings across our 
entire study population.  Furthermore, very few studies have assessed the CYP1B1 Leu432Val 
polymorphism in African American women.  To date, we have identified only one study that 
indicates the possibility of an increase in breast cancer risk among African American women 
carrying at least one copy of the valine allele, but these findings did not reach statistical 
significance (Van Emburgh et al., 2008).  However, these results have not been duplicated, nor 
have they assessed this association with the 2OHE1:16OHE1 EMR.  We have, however, shown 
an association between this polymorphism and the 2OHE1:16OHE1 EMR, a relationship between 
2OHE1:16OHE1 EMR and breast cancer risk, and evidence to suggests that the predictors of the 
breast cancer risk may differ by race.  While we believe that the CYP1B1 Leu432Val 
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polymorphism may indirectly alter breast cancer risk through variations in the 2OHE1:16OHE1 
EMR, we could also imply that the CYP1B1 Leu432Val polymorphism may have an effect on 
other variables by race, therefore establishing a foundation for future research to examine 
whether the 2OHE1:16OHE1 EMR differs by race as well. 
While we observed several associations between known breast cancer risk factors (i.e., 
age and BMI) and the 2OHE1:16OHE1 EMR, we are left to wonder what affects the 
2OHE1:16OHE1 EMR may have on other known risk factors for breast cancer.  Very few studies 
have examined these associations, and the results of such investigations would provide a more 
comprehensive understanding of the role of estrogen in breast cancer risk. 
In conclusion, the objective of this study was to assess the association of the 2OHE1: 
16OHE1 EMR and breast cancer risk; as well as to explore the relationships between this ratio 
and the CYP1B1 Leu432Val polymorphism, mammographic density, and race.  The results of 
our study have been consistent with the findings in the literature, and provide some answers to 
the questions regarding the role of estrogens in breast cancer risk.  Our study has also addressed 
the racial/ethnicity differences that exists in the incidence and mortality of breast cancer, and has 
provided a foundation for future studies to examine the relationship between the 2OHE1: 
16OHE1 EMR and the CYP1B1 Leu432Val polymorphism in breast cancer risk among African 
American women.  This research has established a basis for future studies to build upon, to 
provide a greater understanding of the risk factors and etiology of breast cancer, to develop better 
prevention and treatment methods for all women. 
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APPENDIX A 
TABLE 1.  HIGHLY PENETRANT CANCER SYNDROMES AND BREAST CANCER 
RISK CITATIONS 
1From “Li-Fraumeni Syndrome,” 2004, GeneReviews.  Copyright 1993-2009 by the University 
of Washington, Seattle. 
 
From “PTEN Hamartoma Tumor Syndrome (PHTS),” 2006, GeneReviews.  Copyright 1993-
2009 by the University of Washington, Seattle. 
 
From “Puetz-Jeeghers Syndrome,” 2007, GeneReviews.  Copyright 1993-2009 by the University 
of Washington, Seattle. 
 
From “Ataxia-Telangiectasia,” 2005, GeneReviews.  Copyright 1993-2009 by the University of 
Washington, Seattle. 
 
From “Hereditary Diffuse Gastric Cancer,” 2006, GeneReviews.  Copyright 1993-2009 by the 
University of Washington, Seattle. 
 
From “Bloom‟s Syndrome,” 2006, GeneReviews.  Copyright 1993-2009 by the University of 
Washington, Seattle. 
 
From “Werner Syndrome,” 2007, GeneReviews.  Copyright 1993-2009 by the University of 
Washington, Seattle. 
 
From “Xeroderma Pigmentosum,” 2008, GeneReviews.  Copyright 1993-2009 by the University 
of Washington, Seattle. 
 
From “Nijmegen Breakage Syndrome,” 2005, GeneReviews.  Copyright 1993-2009 by the 
University of Washington, Seattle. 
 
99 
From “Fanconi Anemia,” 2008, GeneReviews.  Copyright 1993-2009 by the University of 
Washington, Seattle. 
 
From “Genetic Insights into Familial Cancers-update and Recent Discoveries,” 2002, Cancer 
Letters, 181, p. 125-164.  Copyright 2002 by Elsevier Science Ireland Ltd. 
 
From “Recognition and Management of Hereditary Breast Cancer Syndromes,” 2004, The 
Oncologist, 9, 13-24.  Copyright 2004 by AlphaMed Press. 
From “Highly Penetrant Hereditary Cancer Syndromes,” 2004, Oncogene, 23, p. 6445-6470.  
Copyright 2004 by Nature Publishing Group. 
 
From “Hereditary Breast Cancer: From Molecular Pathology to Tailored Therapies,” 2008, 
Journal of Clinical Pathology, 61, p. 1073-1082.  Copyright 2008 by David S. Tan, Caterina 
Marchio, and Jorges S. Reis Filho.  From “Germ Line Mutations Associated with Breast Cancer 
Susceptibility,” 2001, European Journal of Cancer, 37, p. 300-321.  Copyright 2001 Elsevier 
Science Ltd. 
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APPENDIX B 
TABLE 2.  LOW PENETRANCE BREAST CANCER SUSCEPTIBILITY VARIANTS 
CITATIONS 
From “A systematic Review of Genetics Polymorphisms and Breast Cancer Risk,” 1999, Alison 
M. Dunning, Catherine S. Healey, Paul D. P. Pharoah, M. Dawn Teare, Bruce A. J. Ponder, and 
Douglas F. Easton.   
 
From “Susceptibility to Breast Cancer: Hereditary Syndromes and Low Penetrance Genes,” 
2006, 2007, Breast Disease, 27, p. 21-50.  Copyright 2006, 2007 by IOS Press and authors.   
 
From “Genetic Predisposition to Breast Cancer: Past, Present, and Future,” 2008, Annual Review 
of Genomics and Human Genetics, 9, p. 321-345.  Copyright 2008 by Annual Reviews.   
 
From “Polygenes, Risk Prediction, and Targeted Prevention of Breast Cancer,” 2008, New 
England Journal of Medicine, 358, p. 2796-2803.  Copyright 2008 Massachusetts Medical 
Society.   
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